{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:45:49Z","timestamp":1793166349175,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013798","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000}}],"reference-count":656,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013798.pub2","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T07:19:06Z","timestamp":1683184746000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Angela","family":"Aldin","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Besiroglu","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Adams","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Piechotta","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Hornbach","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Dressen","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Goldkuhle","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Maisch","sequence":"additional","affiliation":[{"name":"Department of Urology; University of Ulm; Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Department of Urology, Uro-oncology, Special Urological and Robot-assisted Surgery; University Hospital of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"18 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"Abstract 5104","DOI":"10.1200\/jco.2007.25.18_suppl.5104","article-title":"Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma","volume":"25","author":"Jonasch","year":"2007","journal-title":"Journal of Clinical Oncology. Conference: ASCO Annual Meeting"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cncr.24685","article-title":"Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis","volume":"116","author":"Jonasch","year":"2010","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0003|cit3","unstructured":"Atkins MB Hidalgo M Stadler W Logan T Dutcher JP Hudes G A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma Proceedings of the American Society of Clinical Oncology 2002 10a, Abstract 36"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Annals of Oncology"},{"issue":"18S","key":"10.1002\/14651858.CD013798.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/jco.2006.24.18_suppl.lba4","article-title":"A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)","volume":"24","author":"Hudes","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO Annual Meeting Proceedings"},{"issue":"22","key":"10.1002\/14651858.CD013798.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"2-3","key":"10.1002\/14651858.CD013798.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1359-6349(09)71493-4","article-title":"Evaluation of adverse event-related hospitalizations in patients with advanced renal cell carcinoma on treatment with temsirolimus or interferon-alfa: results from a phase 3 randomized trial","volume":"7","author":"Rajagopalan","year":"2009","journal-title":"European Journal of Cancer, Supplement"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1200\/jco.2010.28.15_suppl.4525","article-title":"Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)","volume":"28","author":"Halabi","year":"2010","journal-title":"Journal of Clinical Oncology. Conference: ASCO Annual Meeting"},{"issue":"2-3","key":"10.1002\/14651858.CD013798.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6349(09)71456-9","article-title":"First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): An update on overall survival","volume":"7","author":"Melichar","year":"2009","journal-title":"European Journal of Cancer, Supplement"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0010|cit10","first-page":"29","article-title":"Predictive biomarkers of overall survival in patients with metastatic renal cell carcinoma treated with IFNalpha +\/- bevacizumab: results from CALGB 90206 (alliance)","volume":"OF1 - OF8","author":"Nixon","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"15S Pt 1","key":"10.1002\/14651858.CD013798.pub2-BIB0011|cit11","first-page":"239","article-title":"Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206","volume":"27","author":"Rini","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD013798.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"33","key":"10.1002\/14651858.CD013798.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"18S","key":"10.1002\/14651858.CD013798.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/jco.2006.24.18_suppl.4523","article-title":"Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC)","volume":"24","author":"Bukowski","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO Annual Meeting Proceedings"},{"issue":"29","key":"10.1002\/14651858.CD013798.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/jco.2011.29.15_suppl.4634","article-title":"Effect of sunitinib (Su) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN)","volume":"29","author":"Blagoev","year":"2011","journal-title":"Journal of Clinical Oncology. Conference: ASCO Annual Meeting"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"ix269","DOI":"10.1016\/S0923-7534(20)33384-6","article-title":"Sunitinib (Su) dosing schedule and data collection timepoints: Impact on quality of life (QoL) outcomes in metastatic renal cell carcinoma (mRCC)","volume":"9","author":"Bushmakin","year":"2012","journal-title":"Annals of Oncology"},{"issue":"15S Pt I","key":"10.1002\/14651858.CD013798.pub2-BIB0018|cit18","first-page":"330","article-title":"Quality of life (QoL) with sunitinib versus interferon-alfa (IFN) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): final results","volume":"27","author":"Cappelleri","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/annonc\/mdp067","article-title":"Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population","volume":"20","author":"Castellano","year":"2009","journal-title":"Annals of Oncology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD013798.pub2-BIB0020|cit20","first-page":"189","article-title":"Health-related quality of life (HrQoL) in metastatic renal cell carcinoma (mRCC) patients receiving sunitinib (Su) or interferon (IFN)-alfa in a randomized phase III trial: updated geographic analysis","volume":"19","author":"Cella","year":"2009","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0959-8049(11)71109-1","article-title":"Comparison of health-related quality of life (HrQoL) in patients reporting the same adverse event (AE) fatigue on different treatments","volume":"47","author":"Cella","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"22","key":"10.1002\/14651858.CD013798.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.2007.13.5145","article-title":"Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial","volume":"26","author":"Cella","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"A283","DOI":"10.1016\/S1098-3015(10)74389-8","article-title":"Final quality of life (QoL) results with geographical analysis for sunitinib versus interferon-alfa, as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)","volume":"12","author":"Cella","year":"2009","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1200\/jco.2009.27.15_suppl.6529","article-title":"Quality of life (QoL) with sunitinib versus interferon-alfa (IFN-alpha) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results","volume":"1","author":"Cella","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013798.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00761-007-1243-7","article-title":"Sunitinib vs interferon-alpha for the treatment of metastatic renal cell carcinoma.","volume":"13","author":"Doehn","year":"2007","journal-title":"Onkologe"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0026|cit26","first-page":"S644","article-title":"Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa","volume":"2","author":"Figlin","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"15S Pt 1","key":"10.1002\/14651858.CD013798.pub2-BIB0027|cit27","first-page":"256","article-title":"Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)","volume":"26","author":"Figlin","year":"2008","journal-title":"Journal of clinical oncology: ASCO annual meeting proceedings"},{"issue":"22","key":"10.1002\/14651858.CD013798.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"18S","key":"10.1002\/14651858.CD013798.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/jco.2006.24.18_suppl.lba3","article-title":"Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)","volume":"24","author":"Motzer","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0031|cit31","first-page":"viii190","article-title":"Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)","volume":"19 (S8)","author":"Negrier","year":"2008","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0032|cit32","first-page":"260","article-title":"Superior efficacy of sunitinib compared with interferon as first-line therapy in patients with metastatic renal cell carcinoma","volume":"6","author":"Patel","year":"2007","journal-title":"American Journal of Hematology\/Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/jco.2010.28.15_suppl.4594","article-title":"TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-alpha)","volume":"28","author":"Patil","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013798.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2012.149","article-title":"Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-alpha","volume":"106","author":"Patil","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ncponc1283","article-title":"Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma","volume":"6","author":"Pickering","year":"2009","journal-title":"Nature Clinical Practice Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1558-7673(11)70151-3","article-title":"Phase III study of sunitinib malate (SU11248) versus interferon-\u03b1 as first-line treatment in patients with metastatic renal cell carcinoma","volume":"5","author":"Reddy","year":"2006","journal-title":"Clinical Genitourinary Cancer"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1200\/jco.2013.31.6_suppl.407","article-title":"Predicting survival in metastatic RCC on sunitinib using MASS criteria: evaluation of a large multicentered prospective phase III trial","volume":"31","author":"Smith","year":"2013","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0038|cit38","first-page":"182","article-title":"Overall survival with sunitinib versus interferon-alfa (IFN) as first-line treatment for metastatic renal cell carcinoma (mRCC)","volume":"8","author":"Szczylik","year":"2009","journal-title":"European Urology, Supplements"},{"issue":"2-3","key":"10.1002\/14651858.CD013798.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1359-6349(09)71467-3","article-title":"Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial","volume":"7","author":"Yang","year":"2009","journal-title":"European Journal of Cancer, Supplement"},{"issue":"18S","key":"10.1002\/14651858.CD013798.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/jco.2006.24.18_suppl.4501","article-title":"Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naive patients with metastatic renal cell carcinoma (mRCC)","volume":"24","author":"Escudier","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD013798.pub2-BIB0042|cit42","first-page":"2305","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/0284185116642634","article-title":"Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study","volume":"58","author":"Felsch","year":"2017","journal-title":"Acta Radiologica"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"Abstract 5025","DOI":"10.1200\/jco.2007.25.18_suppl.5025","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results","volume":"25","author":"Szczylik","year":"2007","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0045|cit45","unstructured":"Sorafenib tosylate with or without recombinant interferon alpha-2b in treating patients with metastatic kidney cancer https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00126594"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejca.2011.05.017","article-title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial","volume":"48","author":"Cella","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Pickard AS Cella D Duh MS Guerin A Mishagina N Antras L Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial Journal of Clinical Oncology 2011","DOI":"10.1200\/jco.2011.29.15_suppl.9096"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/jco.2011.29.7_suppl.313","article-title":"A randomized, double-blind phase III study (VEG105192) of pazopanib (paz) versus placebo (pbo) in patients with advanced\/metastatic renal cell carcinoma (mRCC): updated safety results","volume":"29","author":"Sternberg","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0050|cit50","first-page":"viii10","article-title":"Randomized, double-blind phase III study of pazopanib in patients with advanced\/metastatic renal cell carcinoma (mRCC): final overall survival (OS) results","volume":"8","author":"Sternberg","year":"2010","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0052|cit52","first-page":"S645","article-title":"Baseline biomarker trend analysis of a randomized phase 2\/3 study of naptumomab estafenatox plus IFN-a vs IFN-a in advanced renal cell carcinoma","volume":"2","author":"Eisen","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.18632\/oncotarget.2922","article-title":"Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2\/3 study of naptumomab estafenatox plus IFN-\u03b1 versus IFN-\u03b1","volume":"6","author":"Elkord","year":"2015","journal-title":"Oncotarget"},{"issue":"13","key":"10.1002\/14651858.CD013798.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-15-0580","article-title":"A randomized phase II\/III study of naptumomab estafenatox + IFN\u03b1 versus IFN\u03b1 in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis","volume":"22","author":"Hawkins","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0055|cit55","unstructured":"ABR-217620\/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma clinicaltrials.gov\/show\/NCT00420888"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0056|cit56","first-page":"1461","article-title":"Subgroup analysis and updated results of a randomized study comparing sorafenib plus interleukin-2 versus sorafenib alone as first-line treatment in metastatic renal cell carcinoma","volume":"30","author":"Procopio","year":"2010","journal-title":"Anticancer Research"},{"issue":"2-3","key":"10.1002\/14651858.CD013798.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1359-6349(09)71440-5","article-title":"A randomized, prospective, phase 2 study, with sorafenib (So) and interleukin-2 (IL-2) versus So alone as first line treatment in advanced renal cell cancer (RCC): ROSORC trial","volume":"7","author":"Procopio","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/jco.2013.31.6_suppl.356","article-title":"Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): final update of the ROSORC trial","volume":"31","author":"Procopio","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"15S Pt 1","key":"10.1002\/14651858.CD013798.pub2-BIB0059|cit59","first-page":"258","article-title":"A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): ROSORC trial","volume":"27","author":"Procopio","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1093\/annonc\/mdt375","article-title":"Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial","volume":"24","author":"Procopio","year":"2013","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/bjc.2011.103","article-title":"Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial","volume":"104","author":"Procopio","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"Abstract 4589","DOI":"10.1200\/jco.2010.28.15_suppl.4589","article-title":"Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 versus So alone as first-line treatment in metastatic renal cell carcinoma","volume":"28","author":"Procopio","year":"2010","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"e15589","DOI":"10.1200\/jco.2013.31.15_suppl.e15589","article-title":"Proof of concept of correlation between progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with advanced renal-cell carcinoma (mRCC): final results of a randomized phase II study comparing sorafenib plus interleukin-2 (IL-2) versus sorafenib alone: the ROSORC trial","volume":"31","author":"Verzoni","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1200\/jco.2012.30.15_suppl.4625","article-title":"Updated results on long-term overall survival (OS) of the French randomized phase II trial TORAVA in metastatic renal cell carcinoma (mRCC) patients","volume":"30","author":"Bay","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"Abstract 4516","DOI":"10.1200\/jco.2010.28.15_suppl.4516","article-title":"Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma? Results of the randomized TORAVA phase II trial","volume":"28","author":"Escudier","year":"2010","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"Negrier","year":"2011","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"ix14","DOI":"10.1016\/S0923-7534(20)34326-X","article-title":"Randomized phase IIIb trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from intoract","volume":"9","author":"Rini","year":"2012","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","article-title":"Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial","volume":"32","author":"Rini","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Ravaud A Bajetta E Kay AC Pelov D Hollaender N Rouyrre N Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma Journal of Clinical Oncology: ASCO annual meeting proceedings 2010","DOI":"10.1200\/jco.2010.28.15_suppl.tps238"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/annonc\/mdv170","article-title":"RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alpha-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Ravaud","year":"2015","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1200\/jco.2013.31.15_suppl.4576","article-title":"Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon alpha-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results","volume":"31","author":"Ravaud","year":"2013","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/jco.2014.32.15_suppl.4581","article-title":"Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN)","volume":"32","author":"Beaumont","year":"2014","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0073|cit73","first-page":"S18","article-title":"Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ","volume":"2","author":"Bjarnason","year":"2018","journal-title":"Kidney cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2017.35.15_suppl.4574","article-title":"Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ","volume":"35","author":"Bjarnason","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1200\/jco.2013.31.6_suppl.346","article-title":"Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study","volume":"31","author":"Cella","year":"2013","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1200\/jco.2013.31.6_suppl.366","article-title":"Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ)","volume":"31","author":"Guo","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-018-0617-1","article-title":"Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial","volume":"11","author":"Guo","year":"2018","journal-title":"Journal of Hematology and Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1200\/jco.2013.31.15_suppl.4569","article-title":"Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms","volume":"31","author":"Johnson","year":"2013","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/jco.2014.32.4_suppl.405","article-title":"Development and validation of a prognostic nomogram for progression-free and overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib","volume":"32","author":"Kattan","year":"2014","journal-title":"Journal of Clinical Oncology. Conference"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"ix13","DOI":"10.1016\/S0923-7534(20)34325-8","article-title":"Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial","volume":"9","author":"Motzer","year":"2012","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"VI283","DOI":"10.1093\/annonc\/mdw373.38","article-title":"Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC)-a validation study","volume":"27 Suppl 6","author":"Pond","year":"2016","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12885-020-6708-8","article-title":"Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies","volume":"20","author":"Sheng","year":"2020","journal-title":"BMC Cancer"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"e16588","DOI":"10.1200\/JCO.2018.36.15_suppl.e16588","article-title":"Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): a pooled China subgroup analysis from COMPARZ studies","volume":"36","author":"Sheng","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0085|cit85","first-page":"25","article-title":"Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis","volume":"2 Suppl 1","author":"Tannir","year":"2018","journal-title":"Kidney Cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/jco.2013.31.15_suppl.4519","article-title":"Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study)","volume":"31","author":"Xu","year":"2013","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","article-title":"SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer","volume":"68","author":"Eichelberg","year":"2015","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0088|cit88","first-page":"5","article-title":"SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (So) \/ sunitinib (Su) versus Su\/So in the treatment of metastatic renal cell cancer (mRCC)","volume":"5","author":"Fischer Von Weikersthal","year":"2014","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0089|cit89","first-page":"237","article-title":"Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (So) followed by sunitinib (Su) versus sunitinib followed by sorafenib in patients with advanced \/ metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study)-Safety interim analysis results","volume":"6","author":"Fischer Von Weikersthal","year":"2012","journal-title":"Onkologie"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/jco.2014.32.15_suppl.4567","article-title":"Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (So)\/sunitinib (Su) versus Su\/So in the treatment of metastatic renal cell cancer (mRCC)","volume":"32","author":"Goebell","year":"2014","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1200\/jco.2014.32.4_suppl.393","article-title":"SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (So)\/sunitinib (Su) versus Su\/So in the treatment of metastatic renal cell cancer (mRCC)","volume":"32","author":"Michel","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/jco.2012.30.15_suppl.4539","article-title":"Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (So) followed by sunitinib (Su) versus sunitinib followed by sorafenib in patients with advanced\/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): safety interim analysis results","volume":"30","author":"Michel","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.11.001","article-title":"SWITCH II: phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11)","volume":"107","author":"Retz","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"15S pt I","key":"10.1002\/14651858.CD013798.pub2-BIB0094|cit94","first-page":"273","article-title":"Efficacy and safety of first-line bevacizumab (BEV) plus interferon-a2a (IFN) in patients (pts) >65 years with metastatic renal cell carcinoma (mRCC)","volume":"26","author":"Bajetta","year":"2008","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"13","key":"10.1002\/14651858.CD013798.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15S Pt 1","key":"10.1002\/14651858.CD013798.pub2-BIB0096|cit96","first-page":"239","article-title":"Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon alfa-2a (IFN) in metastatic renal cell carcinoma (mRCC)","volume":"27","author":"Escudier","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"Abstract 3","DOI":"10.1200\/jco.2007.25.18_suppl.3","article-title":"A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab\/interferon-a2a vs placebo\/interferon-\u03b12a as first-line therapy in metastatic renal cell carcinoma","volume":"25","author":"Escudier","year":"2007","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"9605","key":"10.1002\/14651858.CD013798.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00761-008-1393-2","article-title":"Bevacizumab plus interferon alfa-2a in the treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III study","volume":"14","author":"Sommerauer","year":"2008","journal-title":"Onkologe"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/jco.2016.34.2_suppl.561","article-title":"Differential overall survival (OS) results in RECORD-3 study based on three distinct mRCC molecular subgroups classified by BAP1 and\/or PBRM1 mutations","volume":"34","author":"Hsieh","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0101|cit101","first-page":"10","article-title":"Differential overall survival results in RECORD-3 study based on three distinct clear cell metastatic renal cell carcinoma molecular subgroups classified by BAP1 and\/ or PBRM1 mutations","volume":"118 Suppl 5","author":"Hsieh","year":"2016","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0102|cit102","first-page":"13","article-title":"Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next-generation sequencing (NGS): results from RECORD-3","volume":"5","author":"Hsieh","year":"2015","journal-title":"BJU International"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma","volume":"71","author":"Hsieh","year":"2017","journal-title":"European Urology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1200\/jco.2015.33.15_suppl.4554","article-title":"Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC)","volume":"33","author":"Knox","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0105|cit105","doi-asserted-by":"crossref","unstructured":"Knox JJ Kay AC Schiff E Hollaender N Rouyrre N Ravaud A First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology: ASCO annual meeting proceedings 2010","DOI":"10.1200\/jco.2010.28.15_suppl.tps232"},{"issue":"25","key":"10.1002\/14651858.CD013798.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2013.54.6911","article-title":"Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma","volume":"32","author":"Motzer","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/jco.2013.31.15_suppl.4504","article-title":"Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)","volume":"31","author":"Motzer","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clgc.2016.05.008","article-title":"Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial","volume":"15","author":"Hutson","year":"2017","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(16)31330-2","article-title":"Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma","volume":"51","author":"Hutson","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0110|cit110","first-page":"1287","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)","volume":"31","author":"Hutson","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"x82","DOI":"10.1093\/annonc\/mdx661.004","article-title":"First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma (mRCC): subgroup analysis of data from a phase III trial","volume":"28","author":"Sheng","year":"2017","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2018-0442","article-title":"First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of phase III data","volume":"15","author":"Sheng","year":"2019","journal-title":"Future Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0959-8049(16)31435-6","article-title":"A prospective randomized phase-II trial with temsirolimus vs. sunitinib in non-clear renal cell carcinoma. A study of the CESAR central european society for anticancer drug research-EWIV and interdisciplinary renal cell carcinoma group of the German cancer society (IAGN)","volume":"3","author":"Bergmann","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"7-8","key":"10.1002\/14651858.CD013798.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000508450","article-title":"A randomized phase IIa trial with temsirolimus versus sunitinib in advanced non-clear cell renal cell carcinoma: an intergroup study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society","volume":"43","author":"Bergmann","year":"2020","journal-title":"Oncology Research and Treatment"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/bjc.2015.313","article-title":"A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results","volume":"113","author":"Eisen","year":"2015","journal-title":"British Journal of Cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/jco.2013.31.15_suppl.4506","article-title":"Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients","volume":"31","author":"Eisen","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Eisen T Shparyk Y MacLeod NJ Wallenstein G Temple G Khder Y Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): results from an open-label, phase II study Journal of Clinical Oncology (Conference) 2012","DOI":"10.1200\/jco.2012.30.15_suppl.e15037"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s10637-013-9962-7","article-title":"Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study","volume":"31","author":"Eisen","year":"2013","journal-title":"Investigational New Drugs"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/jco.2013.31.6_suppl.355","article-title":"Treatment benefit of tivozanib hydrochloride versus sorafenib on health-related quality of life (HRQoL) among patients (pts) with advanced\/metastatic renal cell carcinoma (mRCC): TIVO-1 study results","volume":"31","author":"Cella","year":"2013","journal-title":"Journal of Clinical Oncology. Conference"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"ix262","DOI":"10.1016\/S0923-7534(20)33362-7","article-title":"Detailed comparison of the safety of tivozanib versus sorafenib in patients with advanced\/metastatic renal cell carcinoma (mRCC) from a phase 3 trial","volume":"9","author":"Eisen","year":"2012","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1200\/jco.2015.33.15_suppl.4557","article-title":"Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902)","volume":"33","author":"Hutson","year":"2015","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/jco.2013.31.6_suppl.354","article-title":"Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"31","author":"Hutson","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0123|cit123","first-page":"89","article-title":"Fewer dose adjustments with tivozanib vs. sorafenib in the phase III TIVO-1 study in advanced renal cell carcinoma (RCC)","volume":"52","author":"Hutson","year":"2013","journal-title":"Urologe"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1200\/jco.2013.31.15_suppl.4564","article-title":"Rates of dose adjustment in patients treated with tivozanib versus sorafenib in the phase III TIVO-1 study","volume":"31","author":"Hutson","year":"2013","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2217\/fon.14.120","article-title":"Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial","volume":"10","author":"Mehta","year":"2014","journal-title":"Future Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0126|cit126","first-page":"14","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial","volume":"2","author":"Motzer","year":"2012","journal-title":"BJU International"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1569-9056(13)60373-5","article-title":"Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from the phase III randomized, open-label, multicenter TIVO-1 trial","volume":"11","author":"Motzer","year":"2012","journal-title":"European Urology, Supplements"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/jco.2013.31.6_suppl.350","article-title":"Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma","volume":"31","author":"Motzer","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"30","key":"10.1002\/14651858.CD013798.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0130|cit130","doi-asserted-by":"crossref","unstructured":"Motzer RJ Nosov D Eisen T Bondarenko I Lesovoy V Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial Clinical Advances in Hematology & Oncology 2012 4 6","DOI":"10.1200\/jco.2012.30.15_suppl.4501"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/jco.2013.31.6_suppl.364","article-title":"Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib","volume":"31","author":"Motzer","year":"2013","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0132|cit132","first-page":"89","article-title":"Tivozanib in patients treatment-naive for mRCC in the TIVO-1 study","volume":"52","author":"Sternberg","year":"2013","journal-title":"Der Urologe"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1200\/jco.2013.31.15_suppl.4513","article-title":"Tivozanib in patients treatment-naive for metastatic renal cell carcinoma: a subset analysis of the phase III TIVO-1 study","volume":"31","author":"Sternberg","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"ix261","DOI":"10.1016\/S0923-7534(20)33447-5","article-title":"Quality of life (QoL) among renal cell carcinoma (RCC) patients in a randomized double blind cross-over patient preference study of pazopanib (P) versus sunitinib (S)","volume":"9","author":"Cella","year":"2012","journal-title":"Annals of Oncology"},{"issue":"14","key":"10.1002\/14651858.CD013798.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cncr.29655","article-title":"Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma","volume":"122","author":"Lai","year":"2016","journal-title":"Cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/jco.2015.33.15_suppl.4507","article-title":"Final clinical results of a randomized phase II international trial of everolimus vs. Sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN)","volume":"33","author":"Armstrong","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0139|cit139","doi-asserted-by":"crossref","unstructured":"Armstrong AJ Halabi S Eisen T Stadler WM Jones RR Vaishampayan UN ASPEN: a randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma Journal of Clinical Oncology: ASCO annual meeting proceedings 2013","DOI":"10.1200\/jco.2013.31.15_suppl.tps4590"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0140|cit140","first-page":"16","article-title":"Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma","volume":"16","author":"Armstrong","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2016.34.15_suppl.4563","article-title":"A randomized phase II trial of interleukin-2\/interferon-alpha plus bevacizumab versus interleukin-2\/interferon-alpha in metastatic renal cell carcinoma (mRCC): results from the Danish renal cancer group (DARENCA) study 1","volume":"34","author":"Donskov","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/0284186X.2018.1433324","article-title":"A randomized phase II trial of interleukin-2 and interferon-\u03b1 plus bevacizumab versus interleukin-2 and interferon-\u03b1 in metastatic renal-cell carcinoma (mRCC): results from the Danish renal cancer group (DaRenCa) study-1","volume":"57","author":"Donskov","year":"2018","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0143|cit143","doi-asserted-by":"crossref","unstructured":"Rini BI Gruenwald V Fishman MN Melichar B Ueda T Bair AH Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): unblinded results from a randomized phase II study Journal of Clinical Oncology: ASCO annual meeting proceedings 2013","DOI":"10.1200\/jco.2013.31.6_suppl.lba349"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0144|cit144","first-page":"S657","article-title":"Randomised phase II trial of axitinib with or without dose titration in first-line metastatic renal cell carcinoma (mRCC): efficacy and pharmacokinetic (PK) analyses","volume":"2","author":"Rini","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.euo.2019.06.004","article-title":"Temsirolimus versus pazopanib (TemPa) in patients with advanced clear-cell renal cell carcinoma and poor-risk features: a randomized phase II trial","volume":"3","author":"Tannir","year":"2019","journal-title":"European Urology Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.euo.2019.06.004","article-title":"Temsirolimus versus pazopanib (TemPa) in patients with advanced clear-cell renal cell carcinoma and poor-risk features: a randomized phase II trial","volume":"3","author":"Tannir","year":"2020","journal-title":"European Urology Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.euo.2019.06.004","article-title":"Temsirolimus versus pazopanib (TemPa) in patients with advanced clear-cell renal cell carcinoma and poor-risk features: a randomized phase II trial","volume":"3","author":"Tannir","year":"2020","journal-title":"European Urology Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1200\/JCO.2018.36.6_suppl.583","article-title":"A randomized phase II trial of pazopanib (PAZ) versus temsirolimus (TEM) in patients (PTS) with advanced clear-cell renal cell carcinoma (aCCRCC) of intermediate and poor-risk (the TemPa trial)","volume":"36","author":"Tannir","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2017.35.6_suppl.469","article-title":"Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: a multicenter randomized trial, CROSS-J-RCC","volume":"35","author":"Tomita","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/jco.2014.32.4_suppl.502","article-title":"Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: a multicenter randomized trial, CROSS-J-RCC","volume":"32","author":"Tomita","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/j.clgc.2020.01.001","article-title":"Sunitinib versus sorafenib as initial targeted therapy for mCC-RCC with favorable\/intermediate risk: multicenter randomized trial CROSS-J-RCC","volume":"18","author":"Tomita","year":"2020","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0152|cit152","doi-asserted-by":"crossref","unstructured":"Gschwend J Beeker A De Santis M Brehmer B Zaiss MR Schirrmacher-Memmel S Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced\/metastatic renal cell carcinoma (SWITCH-2 study) Journal of Clinical Oncology: ASCO annual meeting proceedings 2013","DOI":"10.1200\/jco.2013.31.15_suppl.tps4591"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.11.001","article-title":"SWITCH II: phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11)","volume":"107","author":"Retz","year":"2019","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"v295","DOI":"10.1093\/annonc\/mdx371","article-title":"Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)","volume":"28 Suppl 5","author":"Retz","year":"2017","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00120-012-2903-9","article-title":"First line therapy of advanced or metastasized renal cell carcinoma: open, randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2-AN 33\/11).","volume":"51","author":"Rexer","year":"2012","journal-title":"Urologe - Ausgabe A"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00120-014-3459-7","article-title":"First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33\/11)","volume":"53","author":"Rexer","year":"2014","journal-title":"Der Urologe"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0157|cit157","first-page":"75","article-title":"Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib vs pazopanib followed by sorafenib in the treatment of advanced \/ metastatic renal cell carcinoma-design of the SWITCH-2 Study","volume":"7","author":"Schirrmacher-Memmel","year":"2013","journal-title":"Onkologie"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0158|cit158","first-page":"160","article-title":"Cabozantinib for the treatment of advanced renal cell carcinoma in treatment-naive adults","volume":"21","author":"Alba","year":"2019","journal-title":"European Journal of Clinical Pharmacy"},{"issue":"24","key":"10.1002\/14651858.CD013798.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1002\/cncr.33169","article-title":"Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)","volume":"126","author":"Chen","year":"2020","journal-title":"Cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1200\/JCO.2018.36.15_suppl.4556","article-title":"Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203)","volume":"36","author":"Chen","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"vi566","DOI":"10.1093\/annonc\/mdw435.23","article-title":"CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 trial","volume":"27 Suppl 6","author":"Choueiri","year":"2016","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"v623","DOI":"10.1093\/annonc\/mdx440.032","article-title":"Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"28 Suppl 5","author":"Choueiri","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0165|cit165","doi-asserted-by":"crossref","unstructured":"Feldman DR Feuilly M Meng J Lister J Marteau F Morris MJ ECOG score analysis as a proxy for healthrelated quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203) Journal of Clinical Oncology (Conference) 2018","DOI":"10.1200\/JCO.2018.36.15_suppl.e18690"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1634\/theoncologist.2019-0316","article-title":"Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the Alliance A031203 CABOSUN trial","volume":"24","author":"George","year":"2019","journal-title":"Oncologist"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.2018.36.6_suppl.582","article-title":"Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial","volume":"36","author":"George","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2017.35.15_suppl.4505","article-title":"IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)","volume":"35","author":"Atkins","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0169|cit169","first-page":"113","article-title":"A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts)","volume":"40 Suppl 3","author":"Grunwald","year":"2017","journal-title":"Oncology Research and Treatment"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2017.35.6_suppl.431","article-title":"A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts)","volume":"35","author":"McDermott","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0172|cit172","first-page":"S22","article-title":"IMmotion150: novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma","volume":"2 Suppl 1","author":"Pal","year":"2018","journal-title":"Kidney Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2019.37.15_suppl.4515","article-title":"Patient-reported outcomes (PROs) in IMmotion150: atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC)","volume":"37","author":"Pal","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/bju.15058","article-title":"Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma","volume":"126","author":"Pal","year":"2020","journal-title":"BJU International"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2021.01.003","article-title":"Efficacy and safety of atezolizumab plus bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in IMmotion150: a randomized phase 2 clinical trial","volume":"79","author":"Powles","year":"2021","journal-title":"European Urology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013798.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"v624","DOI":"10.1093\/annonc\/mdx440.033","article-title":"IMmotion150: novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)","volume":"28","author":"Powles","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/j.annonc.2020.08.783","article-title":"Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy","volume":"31 Suppl 4","author":"Albiges","year":"2020","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial","volume":"81","author":"Albiges","year":"2021","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"e000798","DOI":"10.1136\/esmoopen-2020-000798","article-title":"European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate\/poor-risk advanced renal cell carcinoma","volume":"5","author":"Ali","year":"2020","journal-title":"ESMO Open"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0181|cit181","doi-asserted-by":"crossref","unstructured":"Branchoux S N\u00e9grier S de Peretti C Malcolm B May J Mari\u00e9 L PCN214 cost-effectiveness analysis of nivolumab in combination with ipilimumab versus sunitinib for the first-line treatment of intermediate- to poor-risk advanced renal cell carcinoma in France Value in Health 2019 S477","DOI":"10.1016\/j.jval.2019.09.410"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0182|cit182","doi-asserted-by":"crossref","unstructured":"Cakar E May J Malcolm B Gooden KM Klijn S PCN421 stability of lifetime overall survival estimates of nivolumab+ipilimumab IN first-line advanced\/metastatic intermediate- or poor-risk renal cell carcinoma Value in Health 2019 S517 8","DOI":"10.1016\/j.jval.2019.09.614"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"v383","DOI":"10.1093\/annonc\/mdz249.047","article-title":"Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results","volume":"30 Suppl 5","author":"Cella","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0184|cit184","first-page":"S49","article-title":"Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results","volume":"4 Suppl 1","author":"Cella","year":"2020","journal-title":"Kidney Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"S562","DOI":"10.1016\/j.annonc.2020.08.786","article-title":"Time to deterioration in quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214","volume":"31 Suppl 4","author":"Cella","year":"2020","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncology"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1200\/JCO.2018.36.15_suppl.3073","article-title":"Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial","volume":"36","author":"Cella","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0188|cit188","doi-asserted-by":"crossref","unstructured":"Characterization of response to nivolumab plus ipilimumab (N1I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (aRCC): CheckMate 214 Annals of Oncology 2018 29 viii309 10","DOI":"10.1093\/annonc\/mdy283.083"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"S563","DOI":"10.1016\/j.annonc.2020.08.789","article-title":"Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I\/P) prognostic risk","volume":"31 Suppl 4","author":"Choueiri","year":"2020","journal-title":"Annals of Oncology"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0190|cit190.1","doi-asserted-by":"crossref","unstructured":"20: 1370-85 (The Lancet Oncology (2019) 20(10) (1370-1385), (S1470204519304139), (10.1016\/S1470-2045(19)30413-9)) Lancet Oncology 2020 21 6 e304","DOI":"10.1016\/S1470-2045(20)30268-0"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0190|cit190.2","doi-asserted-by":"crossref","unstructured":"Correction to Lancet Oncol 2019; 20: 1370-85 (The Lancet Oncology (2019) 20","DOI":"10.1016\/S1470-2045(19)30542-X"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0190|cit190.3","doi-asserted-by":"crossref","unstructured":"(10) (1370-1385), (S1470204519304139), (10.1016\/S1470-2045(19)30413-9)) Lancet Oncology 2020 21 6 e304","DOI":"10.1016\/S1470-2045(20)30268-0"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0191|cit191.1","doi-asserted-by":"crossref","unstructured":"20: 1370-85 (The Lancet Oncology (2019) 20(10) (1370-1385), (S1470204519304139), (10.1016\/S1470-2045(19)30413-9)) Lancet Oncology 2020 21 6 e304","DOI":"10.1016\/S1470-2045(20)30268-0"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0191|cit191.2","doi-asserted-by":"crossref","unstructured":"Correction to Lancet Oncology 2019; 20: 1370-85 (The Lancet Oncology (2019) 20","DOI":"10.1016\/S1470-2045(19)30542-X"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0191|cit191.3","doi-asserted-by":"crossref","unstructured":"(10) (1370-1385), (S1470204519304139), (10.1016\/S1470-2045(19)30413-9)) Lancet Oncology 2020 21 6 e304","DOI":"10.1016\/S1470-2045(20)30268-0"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0192|cit192.1","unstructured":"Correction to nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (The Lancet Oncology (2019) 20"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0192|cit192.2","doi-asserted-by":"crossref","unstructured":"(10) (1370-1385), (S1470204519304139), (10.1016\/S1470-2045(19)30413-9)) Lancet Oncology 2019 20 10 e559","DOI":"10.1016\/S1470-2045(19)30542-X"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0193|cit193.1","unstructured":"Correction to nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (The Lancet Oncology (2019) 20"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0193|cit193.2","doi-asserted-by":"crossref","unstructured":"(10) (1370-1385), (S1470204519304139), (10.1016\/S1470-2045(19)30413-9)) Lancet Oncology 2019 20 10 e559","DOI":"10.1016\/S1470-2045(19)30542-X"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0194|cit194.1","unstructured":"Correction to nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (The Lancet Oncology (2019) 20"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0194|cit194.2","doi-asserted-by":"crossref","unstructured":"(10) (1370\u00e2\u20ac\"1385), (S1470204519304139), (10.1016\/S1470-2045(19)30413-9)) Lancet Oncology 2019 20 10 e559","DOI":"10.1016\/S1470-2045(19)30542-X"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0195|cit195","doi-asserted-by":"crossref","unstructured":"Correction: survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial Journal for Immunotherapy of Cancer 2021 9 5","DOI":"10.1136\/jitc-2020-000891corr1"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0196|cit196","doi-asserted-by":"crossref","unstructured":"Di Rienzo P Zarrelli L Mennini FS Marcellusi A Bini C PCN170 cost-effectiveness of nivolumab in combination with ipilimumab compared to sunitinib in the first-line treatment of advanced or metastatic intermediate- or poor-risk renal cell carcinoma in Italy Value in Health 2019 S469","DOI":"10.1016\/j.jval.2019.09.366"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0197|cit197","first-page":"13","article-title":"Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in CheckMate 214","volume":"13","author":"Escudier","year":"2019","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2019.10.025","article-title":"Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in CheckMate 214","volume":"77","author":"Escudier","year":"2020","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"v621","DOI":"10.1093\/annonc\/mdx440.029","article-title":"CheckMate 214: efficacy and safety of nivolumab 1 ipilimumab (N1I) v sunitinib (S) for treatment-na\u00efve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups","volume":"28","author":"Escudier","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0200|cit200","unstructured":"First-line nivolumab plus ipilimumab is associated with lower costs per responder versus sunitinib among patients with advanced renal cell carcinoma Journal for Immunotherapy of Cancer 2018 6"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0201|cit201","unstructured":"George S Betts K Yang S Du E Johansen J Rao S Nivolumab plus ipilimumab is associated with lower number needed to treat compared with sunitinib for preventing death in advanced renal cell carcinoma Journal for ImmunoTherapy of Cancer. Conference: 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC 2018"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0202|cit202","first-page":"70","article-title":"CheckMate 214 post hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate\/poor-risk patients with previously untreated advanced renal cell carcinoma (aRCC) with sarcomatoid features (sRCC)","volume":"43","author":"Grimm","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0203|cit203","first-page":"42","article-title":"Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial","volume":"41 Suppl 4","author":"Gruenwald","year":"2018","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0204|cit204","first-page":"S5","article-title":"Association between depth of response and overall survival: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214","volume":"4","author":"Gruenwald","year":"2020","journal-title":"Kidney Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0205|cit205","first-page":"74","article-title":"Association between depth of response (DepOR) and overall survival (OS): exploratory analysis of nivolumab + ipilimumab (N+I) vs sunitinib (S) in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214","volume":"43","author":"Gruenwald","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"v382","DOI":"10.1093\/annonc\/mdz249.046","article-title":"Association between depth of response and overall survival: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214","volume":"30 Suppl 5","author":"Gruenwald","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0207|cit207","first-page":"9","article-title":"A phase 3, randomized, openlabel study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma","volume":"114","author":"Hammers","year":"2014","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0208|cit208","doi-asserted-by":"crossref","unstructured":"Hammers HJ Plimack ER Sternberg C McDermott DF Larkin JM Ravaud A CheckMate 214: a phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma Journal of Clinical Oncology. Meeting Abstract | 2015 ASCO Annual Meeting I 2015","DOI":"10.1200\/jco.2015.33.15_suppl.tps4578"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4103\/iju.IJU_153_20","article-title":"CheckMate 214 trial: immune checkpoint regulators for advanced renal cell carcinoma","volume":"36","author":"Jena","year":"2020","journal-title":"Indian Journal of Urology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0210|cit210","doi-asserted-by":"crossref","unstructured":"Lakhdari K Young KC Berling M Gooden KM Holdgate O PCN240 evaluating partitioned survival model and response-based modeling approaches for use in cost-effectiveness analysis: estimating and validating survival outcomes Value in Health 2019 S101 2","DOI":"10.1016\/j.jval.2019.04.361"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1200\/JCO.2019.37.15_suppl.4513","article-title":"CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate\/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features","volume":"37","author":"McDermott","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"viii309","DOI":"10.1093\/annonc\/mdy283.083","article-title":"Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N1I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis","volume":"29 Suppl 8","author":"McDermott","year":"2018","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1200\/JCO.2019.37.7_suppl.564","article-title":"Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214","volume":"37","author":"McDermott","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1200\/JCO.2021.39.15_suppl.6568","article-title":"Long-term trend of qualityadjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the firstline treatment of advanced renal cell carcinoma (aRCC)","volume":"39","author":"Motzer","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1200\/JCO.2020.38.15_suppl.5009","article-title":"Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC)","volume":"38","author":"Motzer","year":"2020","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"e000891","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD013798.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncology"},{"issue":"14","key":"10.1002\/14651858.CD013798.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0219|cit219","unstructured":"Motzer RJ Tannir NM McDermott DF Frontera OA Melichar B Plimack ER Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from CheckMate 214, including overall survival by subgroups Journal for ImmunoTherapy of Cancer 2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0220|cit220","unstructured":"Metastatic renal cell carcinoma (mRCC) patients treated with sunitinib as first-line therapy who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TRC-13004016"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.1016\/j.jval.2019.09.308","article-title":"PCN111 comparison of adverse event costs of nivolumab+ipilimumab versus sunitinib for previously untreated intermediate-\/poor-risk advanced renal cell carcinoma in Switzerland","volume":"22 Suppl 3","author":"Oniangue-Ndza","year":"2019","journal-title":"Value in Health"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/j.jval.2021.11.1025","article-title":"POSC321 estimating long-term survivorship rates for previously untreated intermediate or poor (I\/P) risk advanced renal cell carcinoma (aRCC) patients treated with nivolumab plus ipilimumab (NIVO+IPI): analyses from the CheckMate 214 trial","volume":"25","author":"Paly","year":"2022","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.jval.2019.09.312","article-title":"PCN115 comparison of adverse event costs of nivolumab+ipilimumab versus sunitinib for previously untreated intermediate-\/poor-risk advanced renal cell carcinoma in Spain","volume":"22 Suppl 3","author":"Polanco Sanchez","year":"2019","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"v393","DOI":"10.1093\/annonc\/mdz249.067","article-title":"Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma","volume":"30 Suppl 5","author":"Regan","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"v393","DOI":"10.1093\/annonc\/mdz249.067","article-title":"Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma","volume":"30","author":"Regan","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"S561","DOI":"10.1016\/j.annonc.2020.08.785","article-title":"Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214","volume":"31 Suppl 4","author":"Regan","year":"2020","journal-title":"Annals of Oncology"},{"issue":"24","key":"10.1002\/14651858.CD013798.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1158\/1078-0432.CCR-21-2283","article-title":"Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial","volume":"27","author":"Regan","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD013798.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00120-015-3946-5","article-title":"Therapy of untreated local advanced or metastatic renal cell carcinoma: phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36\/15 of the AUO).","volume":"54","author":"Rexer","year":"2015","journal-title":"Urologe"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"viii309","DOI":"10.1093\/annonc\/mdy283.084","article-title":"Characterization of response to nivolumab plus ipilimumab (N1I) or sunitinib (S) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC): CheckMate 214","volume":"29 Suppl 8","author":"Rini","year":"2018","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.euo.2020.10.005","article-title":"Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. In press. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-2063","volume":"3","author":"Rizzo","year":"2020","journal-title":"European Urology Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"100035","DOI":"10.1016\/j.esmoop.2020.100035","article-title":"Dual immune checkpoint inhibition in metastatic renal cell carcinoma: editorial re.: nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"6","author":"Schmidinger","year":"2021","journal-title":"Esmo Open"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2019.37.7_suppl.547","article-title":"Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"37","author":"Tannir","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1200\/JCO.2018.36.6_suppl.686","article-title":"Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced renal cell carcinoma (aRCC; CheckMate 214)","volume":"36","author":"Tannir","year":"2018","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2020.38.6_suppl.609","article-title":"Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"38","author":"Tannir","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2021.39.6_suppl.313","article-title":"Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214","volume":"39","author":"Tannir","year":"2021","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2019.37.7_suppl.581","article-title":"Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214","volume":"37","author":"Tannir","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0237|cit237","first-page":"78\u201386","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jjco\/hyz132","article-title":"Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up","volume":"50","author":"Tomita","year":"2019","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jjco\/hyz132","article-title":"Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up","volume":"50","author":"Tomita","year":"2020","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0241|cit241","first-page":"17","article-title":"Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from CheckMate 214, including overall survival by subgroups","volume":"24","author":"Vyas","year":"2018","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-19-2838","article-title":"Patient-reported outcomes from the phase III randomized IMmotion151 trial: atezolizumab bevacizumab versus sunitinib in treatment-naive metastatic renal cell carcinoma","volume":"26","author":"Atkins","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/JCO.2018.36.15_suppl.4511","article-title":"Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Escudier","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0245|cit245","first-page":"41","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"41 Suppl 4","author":"Grullich","year":"2018","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0246|cit246","doi-asserted-by":"crossref","unstructured":"Motzer RJ Powles T Atkins MB Escudier B McDermott DF Alekseev BY Final overall survival and molecular analysis in IMmotion151, apPhase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma JAMA Oncology 2021 23","DOI":"10.1001\/jamaoncol.2021.5981"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2018.36.6_suppl.578","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Motzer","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013798.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/s00120-016-0188-0","article-title":"First-line treatment for advanced renal cell carcinoma: a phase 3, open-label, randomized study of atezolizumab (Anti-PD-L1-Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma (\"IMmotion\") - AN 37\/15 der AUO","volume":"55","author":"Rexer","year":"2016","journal-title":"Urologe"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0249|cit249","doi-asserted-by":"crossref","unstructured":"Rini BI Atkins MB Escudier B Powles T McDermott DF Alekseev BY IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) Cancer Research. Conference: AACR Annual Meeting 2021","DOI":"10.1158\/1538-7445.AM2021-CT188"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1200\/JCO.2019.37.15_suppl.4512","article-title":"Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: iMmotion151 subgroup analysis","volume":"37","author":"Rini","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2020.06.021","article-title":"Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: a prespecified subgroup analysis of the IMmotion151 clinical trial","volume":"79","author":"Rini","year":"2020","journal-title":"European Urology"},{"issue":"10189","key":"10.1002\/14651858.CD013798.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"v359","DOI":"10.1093\/annonc\/mdz249.007","article-title":"Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab 1 axitinib (A 1 Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)","volume":"30 Suppl 5","author":"Albiges","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0254|cit254","first-page":"17","article-title":"Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase 3 JAVELIN renal 101 trial","volume":"17","author":"Bilen","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"v361","DOI":"10.1093\/annonc\/mdz249.009","article-title":"Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)","volume":"30 Suppl 5","author":"Choueiri","year":"2019","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2019.37.7_suppl.544","article-title":"Subgroup analysis from JAVELIN renal 101: outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)","volume":"37","author":"Choueiri","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0258|cit258","first-page":"29","article-title":"JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)","volume":"118 Suppl 5","author":"Choueiri","year":"2016","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0259|cit259","doi-asserted-by":"crossref","unstructured":"Choueiri TK Rini BI Larkin JM Bjarnason GA Gravis G Gurney H Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: phase 3 study (JAVELIN renal 101) Journal of Clinical Oncology 2017 35 15","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4594"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0260|cit260","first-page":"51","article-title":"Efficacy of avelumab + axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN renal 101","volume":"17Suppl 7","author":"Haanen","year":"2021","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2021.39.15_suppl.4574","article-title":"Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN renal 101","volume":"39","author":"Haanen","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1200\/JCO.2020.38.6_suppl.687","article-title":"Evaluation of brain metastasis in JAVELIN renal 101: efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S)","volume":"38","author":"Jonasch","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"vi293","DOI":"10.1093\/annonc\/mdw373.71","article-title":"Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)","volume":"27","author":"Motzer","year":"2016","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"viii724","DOI":"10.1093\/annonc\/mdy424.036","article-title":"JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)","volume":"29 Suppl 8","author":"Motzer","year":"2018","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nature Medicine"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2021.39.15_suppl.4548","article-title":"Association of c-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): long-term follow-up results from JAVELIN renal 101","volume":"39","author":"Tomita","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/JCO.2021.39.6_suppl.302","article-title":"Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN renal 101","volume":"39","author":"Tomita","year":"2021","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2021.39.6_suppl.301","article-title":"Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN renal 101","volume":"39","author":"Tomita","year":"2021","journal-title":"Journal of Clinical Oncology. Conference"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0270|cit270","first-page":"28","article-title":"Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN renal 101","volume":"28","author":"Uemura","year":"2019","journal-title":"Cancer Science"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cas.14294","article-title":"Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN renal 101","volume":"111","author":"Uemura","year":"2020","journal-title":"Cancer Science"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"v386","DOI":"10.1093\/annonc\/mdz249.052","article-title":"Randomized phase III trial of avelumab + axitinib vs sunitinib as firstline treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis","volume":"30 Suppl 5","author":"Uemura","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0273|cit273","first-page":"225","article-title":"Depth of response (DEPOR) analysis and correlation with clinical outcomes from JAVELIN renal 101","volume":"43","author":"Voss","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0274|cit274","unstructured":"Cabozantinib s-malate, crizotinib, volitinib, or sunitinib malate in treating patients with locally advanced or metastatic kidney cancer clinicaltrials.gov\/show\/NCT02761057"},{"issue":"10275","key":"10.1002\/14651858.CD013798.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JCO.2021.39.6_suppl.270","article-title":"Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): results from the randomized phase II SWOG 1500 study","volume":"39","author":"Pal","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JCO.2021.39.6_suppl.270","article-title":"Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): results from the randomized phase II SWOG 1500 study","volume":"39","author":"Pal","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0278|cit278","doi-asserted-by":"crossref","unstructured":"Pal SK Tangen CM Thompson IM Shuch BM Haas NB George DJ A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500 Journal of Clinical Oncology (Conference) 2017","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4599"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.1016\/j.annonc.2021.08.056","article-title":"Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): outcomes in subgroups and toxicity update","volume":"32 Suppl 5","author":"Choueiri","year":"2021","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013798.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2217\/fon-2018-0745","article-title":"Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale","volume":"15","author":"Gruenwald","year":"2019","journal-title":"Future Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0281|cit281","first-page":"25","article-title":"Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (L) + pembrolizumab (P) and sunitinib (S) treatment arms","volume":"44 Suppl 2","author":"Gruenwald","year":"2021","journal-title":"Oncology Research and Treatment"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2021.39.15_suppl.4560","article-title":"Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms","volume":"39","author":"Gruenwald","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2021.39.15_suppl.4562","article-title":"Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms","volume":"39","author":"Hutson","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0284|cit284","first-page":"13","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"13","author":"Motzer","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0285|cit285","doi-asserted-by":"crossref","unstructured":"Motzer RJ Gruenwald V Hutson TE Porta C Powles T Eto M A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma Journal of Clinical Oncology (Conference) 2018","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS706"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0286|cit286","first-page":"S2","article-title":"A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma","volume":"2 Suppl 1","author":"Motzer","year":"2018","journal-title":"Kidney Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0287|cit287","doi-asserted-by":"crossref","unstructured":"Motzer RJ Gruenwald V Hutson TE Porta C Powles T Eto M A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (pts) with metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology (Conference) 2017","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4595"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0288|cit288","first-page":"169","article-title":"A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma (RCC)","volume":"13","author":"Motzer","year":"2017","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2021.39.15_suppl.4502","article-title":"Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"39","author":"Motzer","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.2021.39.6_suppl.269","article-title":"Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)","volume":"39","author":"Motzer","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0291|cit291.1","doi-asserted-by":"crossref","unstructured":"21: 1563-73 (The Lancet Oncology (2020) 21(12) (1563-1573), (S1470204520304368), (10.1016\/S1470-2045(20)30436-8)) Lancet Oncology 2020 21 12 e553","DOI":"10.1016\/S1470-2045(20)30699-9"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0291|cit291.2","doi-asserted-by":"crossref","unstructured":"Correction to Lancet Oncol 2020; 21: 1563-73 (The Lancet Oncology (2020) 21","DOI":"10.1016\/S1470-2045(20)30699-9"},{"key":"#cr-split#-10.1002\/14651858.CD013798.pub2-BIB0291|cit291.3","doi-asserted-by":"crossref","unstructured":"(12) (1563-1573), (S1470204520304368), (10.1016\/S1470-2045(20)30436-8)) Lancet Oncology 2020 21 12 e553","DOI":"10.1016\/S1470-2045(20)30699-9"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"S694","DOI":"10.1016\/j.annonc.2021.08.065","article-title":"Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study","volume":"32 Suppl 5","author":"Gafanov","year":"2021","journal-title":"Annals of Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013798.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2020.10.212","article-title":"Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia","volume":"31","author":"Kondoh","year":"2020","journal-title":"Annals of Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2021.39.6_suppl.327","article-title":"Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study","volume":"39","author":"Plimack","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0295|cit295","first-page":"33","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy formetastatic renal cell carcinoma: outcomes in the combined IMDC intermediate-\/poor-risk and sarcomatoid subgroups of the phase 3 Keynote-426 study","volume":"15","author":"Plimack","year":"2019","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/JCO.2020.38.15_suppl.5001","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): updated analysis of KEYNOTE-426","volume":"38","author":"Plimack","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2019.37.7_suppl.543","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study","volume":"37","author":"Powles","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00120-017-0335-2","article-title":"First-line therapy in advanced renal cell carcinoma: a randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39\/16 of the AUO","volume":"56","author":"Rexer","year":"2017","journal-title":"Urologe"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.euo.2021.05.007","article-title":"Characterization and management of treatment-emergent hepatic toxicity in patients with advanced renal cell carcinoma receiving first-line pembrolizumab plus axitinib. Results from the KEYNOTE-426 trial","volume":"5","author":"Rini","year":"2021","journal-title":"European Urology Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2019.37.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate\/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study","volume":"37","author":"Rini","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0304|cit304","doi-asserted-by":"crossref","unstructured":"Rini BI Powles T Chen M Puhlmann M Atkins MB Phase 3 KEYNOTE-426 trial: pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced\/metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology (Conference) 2017","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4597"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0305|cit305","doi-asserted-by":"crossref","unstructured":"Rini BI Powles T Chen M Song Y Puhlmann M Atkins MB KEYNOTE-426: randomized phase III study of pembrolizumab in combination with axitinib versus sunitinib monotherapy in treatment-naive advanced\/metastatic renal cell carcinoma (mRCC) Journal for ImmunoTherapy of Cancer. Conference: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer, SITC 2016","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4597"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0306|cit306","first-page":"40","article-title":"Pembrolizumab plus axitinib vs sunitinib as first-line therapy for metastatic renal cell carcinoma: outcomes by IMDC risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study","volume":"4 Suppl 1","author":"Soulieres","year":"2020","journal-title":"Kidney Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10147-021-02014-7","article-title":"Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study","volume":"27","author":"Tamada","year":"2021","journal-title":"International Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10147-021-02014-7","article-title":"Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study","volume":"27","author":"Tamada","year":"2022","journal-title":"International Journal of Clinical Oncology"},{"issue":"17","key":"10.1002\/14651858.CD013798.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/imt-2020-0034","article-title":"Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma","volume":"12","author":"Zhu","year":"2020","journal-title":"Immunotherapy"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2021.39.15_suppl.4553","article-title":"Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial","volume":"39","author":"Apolo","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0311|cit311","first-page":"42","article-title":"Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial","volume":"107","author":"Basso","year":"2021","journal-title":"Tumori Journal"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0312|cit312","first-page":"24","article-title":"Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial","volume":"44 Suppl 2","author":"Bedke","year":"2021","journal-title":"Oncology Research and Treatment"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2021.39.6_suppl.285","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: the CheckMate 9ER trial","volume":"39","author":"Cella","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","article-title":"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial","volume":"23","author":"Cella","year":"2022","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0315|cit315","doi-asserted-by":"crossref","unstructured":"Choueiri TK Apolo AB Powles T Escudier B Aren OR Shah A A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER) Journal of Clinical Oncology. Meeting Abstract | 2018 ASCO Annual Meeting I 2018","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4598"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.annonc.2020.08.2257","article-title":"Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial","volume":"31 Suppl 4","author":"Choueiri","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.esmoop.2020.100025","article-title":"ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial","volume":"6","author":"Kfoury","year":"2021","journal-title":"ESMO Open"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0319|cit319","first-page":"32","article-title":"Nivolumab\/cabozantinib combo impresses as frontline RCC treatment: combination reduces risk of disease progression or death by 49% versus sunitinib","volume":"48","author":"Mauro","year":"2020","journal-title":"Urology Times"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2021.39.6_suppl.308","article-title":"Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER","volume":"39","author":"Motzer","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00761-020-00891-7","article-title":"Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib: Results of the CheckMate-9ER trial.","volume":"27","author":"Oing","year":"2021","journal-title":"Onkologe"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0322|cit322","first-page":"131","article-title":"Nivolumab plus cabozantinib (N+C) vs sunitinib for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial","volume":"17 Suppl 9","author":"Pook","year":"2021","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1200\/JCO.2021.39.15_suppl.4561","article-title":"Cabozantinib (C) exposureresponse (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC)","volume":"39","author":"Shah","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD013798.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1200\/JCO.2005.07.114","article-title":"Randomized phase II\/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)","volume":"23","author":"Aass","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"viii316","DOI":"10.1093\/annonc\/mdy283.099","article-title":"Everolimus as first-line or after cytokine therapy in patients with metastatic recurrent and\/or unresectable renal cell carcinoma (RCC) (EVERMORE)","volume":"29 Suppl 8","author":"Abdel Hakim","year":"2018","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0326|cit326","first-page":"610","article-title":"Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno- versus hormonotherapy. Preliminary report of immunological and clinical aspects","volume":"6","author":"Adler","year":"1987","journal-title":"Journal of Biological Response Modifiers"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin","year":"2018","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0328|cit328","first-page":"S45","article-title":"Updated results from a phase I study of nivolumab in combination with sunitinib or pazopanib in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"2 Suppl 1","author":"Amin","year":"2018","journal-title":"Kidney Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0329|cit329","unstructured":"Atkins MB Sparano J Fisher RI Weiss GR Margolin KA Aronson FR Randomized phase II trial of high dose IL-2 either alone or in combination with interferon alpha 2B in advanced renal cell carcinoma Proceedings of The American Society of Clinical Oncology 1991"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.1993.11.4.661","article-title":"Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma","volume":"11","author":"Atkins","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0331|cit331","doi-asserted-by":"crossref","unstructured":"Atzpodien J Kirchner H Franzke A Wandert T Probst M Buer J Results of a randomized clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients Proceedings of The American Society of Clinical Oncology 1997 326a, Abstract 1164","DOI":"10.1016\/S0959-8049(97)84539-X"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"S8, A151","DOI":"10.1016\/S0959-8049(97)84539-X","article-title":"A randomized clinical trial comparing sc interleukin-2, sc alpha-2a-interferon, and iv bolus 5-flurouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients","volume":"33","author":"Atzpodien","year":"1997","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0333|cit333","unstructured":"Atzpodien J Kirchner H Bergmann L Oberneder R Jonas U Ganser A 13cis-retinoic acid, IFN-alpha, IL-2 and chemotherapy in advanced renal cell carcinoma: results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Immunotherapy Group (DGCIN) Proceedings of The American Society of Clinical Oncology 1999 448a, Abstract 1727"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1054\/bjoc.2001.2076","article-title":"IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial","volume":"85","author":"Atzpodien","year":"2001","journal-title":"British Journal Of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2004.06.155","article-title":"Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)","volume":"22","author":"Atzpodien","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bjc.6603271","article-title":"Interleukin-2\/interferon-alpha2a\/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)","volume":"95","author":"Atzpodien","year":"2006","journal-title":"British Journal Of Cancer"},{"issue":"2-3","key":"10.1002\/14651858.CD013798.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1359-6349(09)71455-7","article-title":"Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results","volume":"7","author":"Barrios","year":"2009","journal-title":"European Journal of Cancer, Supplement"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"e17516","DOI":"10.1200\/jco.2009.27.15_suppl.e17516","article-title":"Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients","volume":"1","author":"Beaumont","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1634\/theoncologist.2010-0299","article-title":"Patient-reported outcomes in a phase III study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy","volume":"16","author":"Beaumont","year":"2011","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0340|cit340","unstructured":"Berg WJ Bukowski R Thompson JA Nemunaitis J Murphy B Ellerhorst J A randomized phase II trial of recombinant human interleukin-12 (IL-12) versus interferon alpha-2A (IFN) in advanced renal cell carcinoma Proceedings of The American Society of Clinical Oncology 1998 318a, Abstract 1226"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"v622","DOI":"10.1093\/annonc\/mdx440.030","article-title":"Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)","volume":"28 Suppl 5","author":"Bex","year":"2017","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/030089169808400505","article-title":"Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial","volume":"84","author":"Boccardo","year":"1998","journal-title":"Tumori Journal"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"Abstract 5100","DOI":"10.1200\/jco.2007.25.18_suppl.5100","article-title":"Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-a2a in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681","volume":"25 Suppl","author":"Bracarda","year":"2007","journal-title":"Journal Of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1186\/s12885-019-6273-1","article-title":"PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma","volume":"19","author":"Buckley","year":"2019","journal-title":"BMC Cancer"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1200\/JCO.2016.34.15_suppl.4549","article-title":"Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study","volume":"34","author":"Cella","year":"2016","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0346|cit346","first-page":"v328","article-title":"Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial","volume":"28","author":"Choueiri","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of savolitinib vs sunitinib in patients with MET -driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2020.38.15_suppl.5002","article-title":"SAVOIR: a phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC)","volume":"38","author":"Choueiri","year":"2020","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1200\/JCO.2016.34.15_suppl.4550","article-title":"A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial)","volume":"34","author":"Cirkel","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamaoncol.2016.5202","article-title":"Alternating treatment with pazopanib and everolimus vs continuous pazopanib to delay disease progression in patients with metastatic clear cell renal cell cancer: the ROPETAR randomized clinical trial","volume":"3","author":"Cirkel","year":"2017","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"S608","DOI":"10.1016\/j.annonc.2020.08.2074","article-title":"Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients","volume":"31 Suppl 4","author":"Climent Duran","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0352|cit352","unstructured":"Cole BF McDermott D Parker R Youmans A Connolly C Ernstoff M The impact of treatmen with high-dose interleukin-2 (HD IL-2) or subcutaneous (SC) IL-2\/interferon alfa-2b (IFN) on quality of life (QoL) in patients with metastatic renal cell carcinoma (mRCC) Proceedings of The American Society of Clinical Oncology 2003"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1186\/1471-2407-12-598","article-title":"The STAR trial protocol: a randomised multi-stage phase II\/III study of sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced\/metastatic renal cancer","volume":"12","author":"Collinson","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"viii331","DOI":"10.1093\/annonc\/mdy283.140","article-title":"PRISM: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma","volume":"29 Suppl 8","author":"Collinson","year":"2018","journal-title":"Annals of Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2021.39.6_suppl.359","article-title":"Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): results from the phase II nivoren-GETUG AFU 26 trial","volume":"39","author":"Colomba","year":"2021","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1200\/jco.2013.31.6_suppl.365","article-title":"Ten-year follow-up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: results from a randomized trial","volume":"31","author":"Conter","year":"2013","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0357|cit357","first-page":"111","article-title":"Comparison of vinblastine and interferon alpha with 5-flourouracil treatment in metastatic renal cell carcinoma: a preliminary report","volume":"21","author":"Demirci","year":"1999","journal-title":"Erciyes Tip Dergisi"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0358|cit358","unstructured":"de Mulder PH Debruyne FM van Oosterom A Bouffioux C Vermeylen K Sylvester R EORTC randomized phase II study of recombinant interferon alpha and recombinant interferon alpha and gamma in advanced renal cell carcinoma Proceedings of The American Society of Clinical Oncology 1991 166, Abstract 528"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0359|cit359","unstructured":"Dexeus F Logothetis C Chong C Sella A Finn L Phase III study in metastatic renal cell carcinoma comparing combination chemotherapy versus interferon alternating with combination chemotherapy Proceedings of The American Society of Clinical Oncology 1988 131, Abstract 507"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00000421-198908000-00015","article-title":"Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma","volume":"12","author":"Dexeus","year":"1989","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0361|cit361","unstructured":"A phase 2 randomized, double-blind, crossover, controlled, multi-center subject preference study of tivozanib hydrochloride versus sunitinib in the treatment of subjects with metastatic renal cell carcinoma drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010309 2016"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1200\/JCO.1997.15.3.1052","article-title":"Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma","volume":"15","author":"Dubois","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"v891","DOI":"10.1093\/annonc\/mdz394.050","article-title":"Primary efficacy analysis results from the SORCE trial (RE05): adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: an international, randomised double-blind phase III trial led by the MRC CTU at UCL","volume":"30","author":"Eisen","year":"2019","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1464-410x.2000.00880.x","article-title":"Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma","volume":"86","author":"Elhilali","year":"2000","journal-title":"BJU International"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"eS22","DOI":"10.1016\/S0007-4551(20)30283-6","article-title":"BIONIKK: a phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in na\u00efve metastatic kidney cancer","volume":"107","author":"Epaillard","year":"2020","journal-title":"Bulletin du Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0366|cit366","doi-asserted-by":"crossref","unstructured":"Escudier B Szczylik C Eisen T Stadler WM Schwartz B Shan M Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) Annual meeting proceedings of The American Society of Clinical Oncology 2005 380","DOI":"10.1200\/jco.2005.23.16_suppl.lba4510"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0367|cit367","unstructured":"Schmidinger M Sorafenib and bevacizumab as first- line treatment in patients with advanced renal cell carcinoma trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-002851-33-AT 2006"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0368|cit368","unstructured":"Treatment for renal cancer who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-003429-95-ES 2012"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0369|cit369","unstructured":"An open label, dose escalation safety and tolerability trial of the combination of s.c. recombinant human IL-21 (rIL-21) and sunitinib (phase 1) followed by an open label stratified randomized 2-arm trial of rIL-21 plus sunitinib versus sunitinib alone (phase 2a) in subjects with stage IV renal cell carcinoma. Trial phase: 1\/2a who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-005751-16-NL 2007"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0370|cit370","unstructured":"TWIST- randomized prospective phase II study of temsirolimus with or without low-dose interferon alpha in metastatic non-clear renal cell carcinoma- GOIRC STUDY 02\/2008 - TWIST trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007%E2%80%90002556%E2%80%9041%E2%80%90AT 2008"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0371|cit371","unstructured":"A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar\u00ae) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC) - PREST https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-002667-13\/ 2008"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0372|cit372","unstructured":"A phase 2 randomized, double-blind, crossover, controlled, multi-center, subject preference study of tivozanib hydrochloride versus sunitinib in the treatment of subjects with metastatic renal cell carcinoma trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-001730-33-ES 2012"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0373|cit373","unstructured":"Study of the drug substances MLN0128 and MLN0128+MLN1117 compared with everolimus in the treatment of patients with metastatic clear cell renal carcinoma who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-002133-22-FR 2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0374|cit374","unstructured":"A randomized, phase 3, double-blind, placebo-controlled study of Pazopanib with or without abexinostat in patients with locally advanced or metastatic renal cell carcinoma who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018-001495-38-FR 2018"},{"issue":"24","key":"10.1002\/14651858.CD013798.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1002\/cncr.33148","article-title":"Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: final results from a phase II trial","volume":"126","author":"Feldman","year":"2020","journal-title":"Cancer"},{"issue":"24","key":"10.1002\/14651858.CD013798.pub2-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1002\/cncr.33148","article-title":"Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: final results from a phase II trial","volume":"126","author":"Feldman","year":"2020","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0377|cit377","doi-asserted-by":"crossref","unstructured":"Figlin RA Thompson JA Roudet C Lange P Belldegrun A Multi-center randomized placebo controlled phase II\/III trial of CD8(+) tumor infiltrating lymphocyte therapy (CD8(+) TIL)\/recombinant interleukin-2 (IL-2) in metastatic renal cell carcinoma Proceedings of The American Society of Clinical Oncology 1998 318a, Abstract 1225","DOI":"10.1200\/JCO.1999.17.8.2521"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.1999.17.8.2521","article-title":"Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma","volume":"17","author":"Figlin","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0379|cit379","doi-asserted-by":"crossref","unstructured":"Figlin RA Wood CG Patient identification and eligibility insights in the synchronous mRCC population: an update from the ongoing ADAPT* phase 3 study experience Journal of Clinical Oncology (Conference) 2014","DOI":"10.1200\/jco.2014.32.15_suppl.tps4599"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0380|cit380","doi-asserted-by":"crossref","unstructured":"Figlin RA Wood CG Enrollment insights in the synchronous mRCC population: an update from the ongoing ADAPT* phase 3 study experience Journal of Clinical Oncology: ASCO annual meeting proceedings 2014","DOI":"10.1200\/jco.2014.32.15_suppl.tps4599"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"v404","DOI":"10.1093\/annonc\/mdx376.003","article-title":"Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)","volume":"28 Suppl 5","author":"Figlin","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1200\/JCO.2018.36.15_suppl.4557","article-title":"Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care","volume":"36","author":"Figlin","year":"2018","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"10","key":"10.1002\/14651858.CD013798.pub2-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","article-title":"Results of the ADAPT phase 3 study of rocapuldencel-t in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Figlin","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"21","key":"10.1002\/14651858.CD013798.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1200\/JCO.2015.60.9727","article-title":"BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma - a trial of the ECOG-ACRIN cancer research group (E2804)","volume":"33","author":"Flaherty","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0385|cit385","first-page":"540","article-title":"A prospective randomized trial of alpha(2B)-interferon\/gamma- interferon or the combination of advanced metastatic renal cell carcinoma","volume":"7","author":"Foon","year":"1988","journal-title":"Journal of Biological Response Modifiers"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1464-410X.1989.tb05278.x","article-title":"Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study","volume":"64","author":"Fossa","year":"1989","journal-title":"British Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/oxfordjournals.annonc.a058185","article-title":"Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study","volume":"3","author":"Fossa","year":"1992","journal-title":"Annals of Oncology"},{"issue":"13 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"CT083","DOI":"10.1158\/1538-7445.AM2017-CT083","article-title":"Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma","volume":"77","author":"Gao","year":"2017","journal-title":"Cancer Research"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/JCO.2019.37.15_suppl.4501","article-title":"A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx)","volume":"37","author":"Gao","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0390|cit390","doi-asserted-by":"crossref","unstructured":"Gedye C Joshi AJ Zhang AY Martin AJ Joshua AM Harris CA Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): a phase II trial (ANZUP1601) Journal of Clinical Oncology (Conference) 2021","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS367"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0391|cit391","first-page":"S33","article-title":"Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial","volume":"2 Suppl 1","author":"Ghiorghiu","year":"2018","journal-title":"Kidney Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0392|cit392","unstructured":"Gleave M Elhilai M Fradet Y Davis I Venner P Saad F A multicenter randomized, double blind trial of actimmune(r) interferon gamma-1b injection versus placebo for the treatment of metastatic renal cell carcinoma Proceedings of the Annual Meeting of the American Society for Clinical Oncology 1997"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0393|cit393","first-page":"A1274","article-title":"A phase III randomized double-blind placebo-controlled multicenter trial comparing interferon gamma to placebo in patients with metastatic renal cell carcinoma","volume":"157","author":"Gleave","year":"1997","journal-title":"Journal of Urology"},{"issue":"18","key":"10.1002\/14651858.CD013798.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","article-title":"Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian urologic oncology group","volume":"338","author":"Gleave","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"15 Pt 1","key":"10.1002\/14651858.CD013798.pub2-BIB0395|cit395","first-page":"259","article-title":"Interferon-a (IFN), interleukin-2 (IL2) and 5-fluorouracil (5FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC): results of the randomised MRC\/EORTC RE04 trial","volume":"26","author":"Gore","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"9715","key":"10.1002\/14651858.CD013798.pub2-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)61921-8","article-title":"Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04\/EORTC GU 30012): an open-label randomised trial","volume":"375","author":"Gore","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0397|cit397","first-page":"224","article-title":"A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + checkpoint inhibitor (CPI) in first line therapy (PREPARE)","volume":"43","author":"Gruenwald","year":"2020","journal-title":"Oncology Research and Treatment"},{"issue":"10032","key":"10.1002\/14651858.CD013798.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1200\/jco.2015.33.15_suppl.4547","article-title":"Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma","volume":"33","author":"Hainsworth","year":"2015","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-016-0434-9","article-title":"A randomized, open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC)","volume":"11","author":"Hainsworth","year":"2016","journal-title":"Targeted Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11934-002-0004-9","article-title":"A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2\/interferon","volume":"3","author":"Han","year":"2002","journal-title":"Current Urology Reports"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0402|cit402","first-page":"533","article-title":"Comparison of efficacy between interferon-alpha (IFN) plus fluoropyrimidine (FP) and IFN alone in advanced renal cell cancer (RCC): preliminary results","volume":"116","author":"Harima","year":"1990","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/bjc.1998.218","article-title":"Survival in renal cell carcinoma - a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen","volume":"77","author":"Henriksson","year":"1998","journal-title":"British Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3816\/CGC.2006.n.011","article-title":"A phase II study of GW786034 using a randomized discontinuation design in subjects with locally recurrent or metastatic clear-cell renal cell carcinoma","volume":"4","author":"Hutson","year":"2006","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0405|cit405","doi-asserted-by":"crossref","unstructured":"Hutson TE Carthon BC Yorio J Babu S McKean HA Percent IJ Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: results from the CheckMate 920 trial Journal of Clinical Oncology. Conference 2021","DOI":"10.1200\/JCO.2021.39.6_suppl.315"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"viii331","DOI":"10.1093\/annonc\/mdy283.140","article-title":"PRISM: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma","volume":"29 Suppl 8","author":"Collinson","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0407|cit407","unstructured":"A randomised phase II trial comparing two different ways of combining nivolumab and ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2017-001476-33-GB 2018"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0408|cit408","unstructured":"Jager E Heinzer H Grimm MO Krause S Scheuring U Siebels M Randomized phase III trial of the multiple kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) Onkologie 2005 1\u2013275"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/bjc.1998.500","article-title":"A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer","volume":"78","author":"Jayson","year":"1998","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0410|cit410","first-page":"986","article-title":"The effect of immunotherapy based on interferon - alpha in advanced renal cell carcinoma","volume":"31","author":"Jeon","year":"1999","journal-title":"Journal of the Korean Cancer Association"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0411|cit411","unstructured":"A Phase 3 Study of ONO-4538\/BMS-936558 who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-122014 2012"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0412|cit412","unstructured":"NIVOIGERCC who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-jRCTs031180024 2018"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0413|cit413","unstructured":"Randomized parallel group phase II clinical study of sorafenib\/interferon combination therapy and sunitinib monotherapy for advanced renal cell carcinoma who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000001995 2009"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1200\/jco.2004.22.90140.4676","article-title":"Prospective randomized trial of natural interferon-alpha (IFN) versus IFN + cimetidine in advanced renal cell carcinoma with pulmonary metastases","volume":"22","author":"Kinouchi","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00432-006-0095-7","article-title":"Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis","volume":"132","author":"Kinouchi","year":"2006","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0416|cit416","doi-asserted-by":"crossref","first-page":"v381","DOI":"10.1093\/annonc\/mdz249.045","article-title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A","volume":"30 Suppl 5","author":"Larkin","year":"2019","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N","article-title":"Phase III randomized trial of interleukin-2 with or without lymphokine- activated killer cells in the treatment of patients with advanced renal cell carcinoma","volume":"76","author":"Law","year":"1995","journal-title":"Cancer"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2020.38.15_suppl.5034","article-title":"First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): updated follow-up for KEYNOTE-427 cohort B","volume":"38","author":"Lee","year":"2020","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1200\/JCO.2021.39.15_suppl.4509","article-title":"Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: results of a phase 2 trial","volume":"39","author":"Lee","year":"2021","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2020.38.5_suppl.11","article-title":"A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma","volume":"38","author":"Lindskog","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/030089169307900605","article-title":"A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma","volume":"79","author":"Lissoni","year":"1993","journal-title":"Tumori"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0422|cit422","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-11-2442","article-title":"Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma","volume":"18","author":"Liu","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0022-5347(01)66417-6","article-title":"Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha2b in metastatic renal cell carcinoma","volume":"155","author":"Lummen","year":"1996","journal-title":"Journal of Urology"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1200\/jco.2004.22.90140.4742","article-title":"A randomized phase II study of interferon alpha alone or in combination with thalidomide in metastatic renal cancer","volume":"22","author":"Madhusudan","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0425|cit425","unstructured":"McDermott D Flaherty L Clark J Weiss G Logan T Gordon M A randomized phase III trial of high-dose interleukin-2 (HD IL2) versus subcutaneous (SC) Il2\/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC) Proceedings of The American Society of Clinical Oncology 2001 172a, Abstract 685"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/jco.2013.31.6_suppl.345","article-title":"The BEST trial (E2804): a randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC)","volume":"31","author":"McDermott","year":"2013","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1200\/JCO.2020.38.15_suppl.5069","article-title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A","volume":"38","author":"McDermott","year":"2020","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"9286","key":"10.1002\/14651858.CD013798.pub2-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","article-title":"Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up","volume":"11","author":"Minasian","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0431|cit431","first-page":"166","article-title":"Efficacy and safety of everolimus treatment in metastatic renal cell carcinoma","volume":"8","author":"Molina","year":"2009","journal-title":"American Journal of Hematology\/Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/107999001750169934","article-title":"Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha2a for patients with advanced renal cell carcinoma","volume":"21","author":"Motzer","year":"2001","journal-title":"Journal of Interferon and Cytokine Research"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0433|cit433","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejca.2011.12.022","article-title":"Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study","volume":"48","author":"Mulders","year":"2012","journal-title":"European Journal of Cancer"},{"issue":"3B","key":"10.1002\/14651858.CD013798.pub2-BIB0434|cit434","first-page":"2021","article-title":"Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma","volume":"18","author":"Naglieri","year":"1998","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0435|cit435","unstructured":"Interferon alfa with or without isotretinoin in treating patients with metastatic kidney cancer clinicaltrials.gov\/show\/NCT00002737 2004"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0436|cit436","unstructured":"Interferon alfa-2b with or without thalidomide in treating patients with metastatic or unresectable kidney cancer clinicaltrials.gov\/show\/NCT00005966 2003"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0437|cit437","unstructured":"Monoclonal antibody therapy in treating patients with advanced kidney cancer clinicaltrials.gov\/show\/NCT00019539 2009"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0438|cit438","unstructured":"Interferon alfa with or without thalidomide in treating patients with metastatic kidney cancer clinicaltrials.gov\/show\/NCT00027664 2003"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0439|cit439","unstructured":"Interferon alfa with or without interleukin-2 and fluorouracil in treating patients with advanced metastatic kidney cancer clinicaltrials.gov\/show\/NCT00053820 2003"},{"issue":"18S","key":"10.1002\/14651858.CD013798.pub2-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/jco.2006.24.18_suppl.4524","article-title":"Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival","volume":"24","author":"Eisen","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s12032-009-9303-z","article-title":"Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET","volume":"27","author":"Negrier","year":"2010","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0442|cit442","unstructured":"Sequential ATRA then IL-2 for modulation of dendritic cells and treatment of metastatic renal cell cancer clinicaltrials.gov\/show\/NCT00100906 2005"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0443|cit443","unstructured":"Bevacizumab, sorafenib tosylate, and temsirolimus in treating patients with metastatic kidney cancer clinicaltrials.gov\/show\/NCT00378703 2006"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0444|cit444","unstructured":"Interleukin-2 and interferon in treating patients with metastatic kidney cancer clinicaltrials.gov\/show\/NCT00416871 2006"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0445|cit445","unstructured":"A randomized, double blinded, multi-center study 2 study to estimate the efficacy and evaluate the safety and tolerability of sorafenib in combination with AMG 386 or placebo in subjects with metas https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00467025"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0446|cit446","unstructured":"A study evaluating the efficacy and safety of sunitinib with or without bevacizumab in first-line patients with metastatic renal cell cancer (SABRE-R) clinicaltrials.gov\/show\/NCT00491738 2007"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0447|cit447","unstructured":"A study for participants with metastatic renal cell carcinoma clinicaltrials.gov\/show\/NCT00709995 2008"},{"issue":"9","key":"10.1002\/14651858.CD013798.pub2-BIB0448|cit448","first-page":"6","article-title":"Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study","volume":"10","author":"Rini","year":"2012","journal-title":"Clinical Advances in Hematology and Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/annonc\/mdv103","article-title":"Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2015","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clgc.2016.04.005","article-title":"Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma","volume":"14","author":"Rini","year":"2016","journal-title":"Clinical Genitourinary Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12885-018-5224-6","article-title":"Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study","volume":"19","author":"Tomita","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0453|cit453","unstructured":"Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-a in patients with advanced renal cell carcinoma. - DCE-MRI changes in tumour vaculature with Bevacizumab and Interferon in advanced RCC who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-006414-19-GB 2009"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0454|cit454","unstructured":"Sunitinib malate with or without gemcitabine hydrochloride in treating patients with advanced kidney cancer that cannot be removed by surgery clinicaltrials.gov\/show\/NCT01164228 2010"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0455|cit455","doi-asserted-by":"crossref","unstructured":"Study of dovitinib versus sorafenib in patients with metastatic renal cell carcinoma clinicaltrials.gov\/show\/NCT01223027 2010","DOI":"10.1016\/S1040-1741(10)79551-8"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0456|cit456","unstructured":"Rotating pazopanib and everolimus to avoid resistance clinicaltrials.gov\/show\/NCT01408004 2011"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0457|cit457","unstructured":"Evaluate the efficacy of sorafenib in renal cell carcinoma patients after a radical resection of the metastases clinicaltrials.gov\/show\/NCT01444807 2011"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0458|cit458","unstructured":"Everolimus\/sorafenib or sunitinib in patients with metastatic renal cell carcinoma (RCC) clinicaltrials.gov\/show\/NCT01616186 2012"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0459|cit459","unstructured":"Trebananib with or without bevacizumab, pazopanib hydrochloride, sorafenib tosylate, or sunitinib malate in treating patients with advanced kidney cancer clinicaltrials.gov\/show\/NCT01664182 2012"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0460|cit460","unstructured":"A subject treatment preference study of tivozanib hydrochloride versus sunitinib in subjects with metastatic renal cell carcinoma clinicaltrials.gov\/show\/NCT01673386 2012"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0461|cit461","unstructured":"Bevacizumab with or without TRC105 in treating patients with metastatic kidney cancer clinicaltrials.gov\/show\/NCT01727089 2012"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0462|cit462","unstructured":"Study of dalantercept and axitinib in patients with advanced renal cell carcinoma clinicaltrials.gov\/show\/NCT01727336 2012"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0463|cit463","unstructured":"A study comparing AZD2014 vs everolimus in patients with metastatic renal cancer clinicaltrials.gov\/show\/NCT01793636 2013"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0464|cit464","unstructured":"Safety and efficacy study of pazopanib and MK 3475 in advanced renal cell carcinoma (RCC; KEYNOTE-018) clinicaltrials.gov\/show\/NCT02014636 2013"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0465|cit465","unstructured":"This is a study designed to evaluate the effectiveness and safety of AZD6094 in patients with papillary renal cell cancer who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-001858-41-ES 2015"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0466|cit466","unstructured":"Trial of X4P-001 in patients with advanced renal cell carcinoma clinicaltrials.gov\/show\/NCT02667886 2016"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0467|cit467","unstructured":"MLN0128 and MLN0128 + MLN1117 compared with everolimus in the treatment of adults with advanced or metastatic clear-cell renal cell carcinoma clinicaltrials.gov\/show\/NCT02724020 2016"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0468|cit468","unstructured":"Epaillard N Simonaggio A Elaidi R Azzouz F Braychenko E A BIOmarker driven trial with nivolumab and ipilimumab or VEGFR tKi in naive metastatic kidney cancer (BIONIKK) clinicaltrials.gov\/ct2\/show\/NCT02960906"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0469|cit469","unstructured":"Sunitinib followed by avelumab or the reverse for metastatic renal cell carcinoma clinicaltrials.gov\/show\/NCT03035630 2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0470|cit470","unstructured":"Axitinib with or without anti-OX40 antibody PF-04518600 in treating patients with metastatic kidney cancer clinicaltrials.gov\/show\/NCT03092856 2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0471|cit471","unstructured":"CM082 combined with everolimus in chinese patients with metastatic renal cell carcinoma clinicaltrials.gov\/show\/NCT03095040 2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0472|cit472","unstructured":"Trial to assess safety and efficacy of lenvatinib (18 mg vs. 14 mg) in combination with everolimus in participants with renal cell carcinoma clinicaltrials.gov\/ct2\/show\/NCT03173560 2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0473|cit473","unstructured":"High dose IL 2 and entinostat in RCC clinicaltrials.gov\/show\/NCT03501381 2018"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0474|cit474","unstructured":"Axitinib and nivolumab in treating participants with unresectable or metastatic TFE\/translocation renal cell carcinoma clinicaltrials.gov\/show\/NCT03595124 2018"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0475|cit475","unstructured":"CBM588, nivolumab, and ipilimumab in treating patients with stage IV or advanced kidney cancer clinicaltrials.gov\/show\/NCT03829111 2019"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0476|cit476","unstructured":"A study of MK-6482 versus everolimus in participants with advanced renal cell carcinoma (MK-6482-005) clinicaltrials.gov\/show\/NCT04195750 2019"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0477|cit477","unstructured":"Efficacy and safety study of AVB-S6-500 in patients with clear cell renal cell carcinoma clinicaltrials.gov\/show\/NCT04300140 2020"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0478|cit478","unstructured":"Negrier S Escudier B Lasset C Savary J Douillard JY Chevreau C The FNCLCC Crecy trial: interleukin 2 (IL2) + interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (mRCC) Proceedings of The American Society of Clinical Oncology 1996 248, Abstract 629"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0479|cit479","unstructured":"Negrier S Escudier B Douillard JY Lesimple T Rossi JF Viens P Randomized study of interleukin-2 and interferon with or without 5-FU (FUCY study) in metastatic renal cell carcinoma Proceedings of The American Society of Clinical Oncology 1997 326a, Abstract 1161"},{"issue":"18","key":"10.1002\/14651858.CD013798.pub2-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma","volume":"338","author":"Negrier","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD013798.pub2-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2000.18.24.4009","article-title":"Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer","volume":"18","author":"Negrier","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0482|cit482","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/jco.2006.24.18_suppl.4536","article-title":"Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (mRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY duo trial","volume":"24","author":"Negrier","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0483|cit483","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/cncr.23056","article-title":"Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial","volume":"110","author":"Negrier","year":"2007","journal-title":"Cancer"},{"issue":"18","key":"10.1002\/14651858.CD013798.pub2-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1158\/1078-0432.CCR-08-0236","article-title":"Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer","volume":"14","author":"Negrier","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0485|cit485","first-page":"viii271","article-title":"Phase 2 randomized discontinuation trial (RDT) of tivozanib in patients with renal cell carcinoma (RCC): results in patients randomized to tivozanib vs. placebo","volume":"8","author":"Nosov","year":"2010","journal-title":"Annals of Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0486|cit486","first-page":"4550","article-title":"Final analysis of the phase 2 randomized discontinuation trial of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma","volume":"29","author":"Nosov","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD013798.pub2-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-14-3370","article-title":"P0125 a phase 1\/2 trial of BNC105P with everolimus in metastatic renal cell carcinoma","volume":"21","author":"Pal","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1200\/JCO.2021.39.6_suppl.307","article-title":"Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI)","volume":"39","author":"Pal","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00262-009-0773-9","article-title":"Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer","volume":"59","author":"Passalacqua","year":"2010","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0490|cit490","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/jco.2015.33.15_suppl.4553","article-title":"Updated survival results from a randomized, doseranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (MRCC)","volume":"33","author":"Plimack","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0491|cit491","unstructured":"Pyrhonen S Salminen E Lehtonen T Nurmi M Tammela T Juusela H Recombinant interferon alfa-2a (IFN) with vinblastine vs vinblastine alone in advanced renal cell carcinoma (RCC). A phase III study Proceedings of The American Society of Clinical Oncology 1995 253, Abstract 686"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0492|cit492","unstructured":"Pyrhonen S Salminen E Lehtonen T Nurmi M Tammela T Juusela H Recombinant interferon alfa-2a with vinblastine vs vinblastine alone in advanced renal cell carcinoma: a phase III study Proceedings of The American Society of Clinical Oncology 1996 244, Abstract 614"},{"issue":"9","key":"10.1002\/14651858.CD013798.pub2-BIB0493|cit493","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.1999.17.9.2859","article-title":"Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer","volume":"17","author":"Pyrhonen","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/jco.2006.24.18_suppl.4502","article-title":"Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC)","volume":"24","author":"Ravaud","year":"2006","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings 2006"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0495|cit495","first-page":"1","article-title":"PR phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)","volume":"27","author":"Ravaud","year":"2016","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00120-017-0343-2","article-title":"First-line therapy in advanced renal cell carcinoma: a randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38\/15 of the AUO.","volume":"56","author":"Rexer","year":"2017","journal-title":"Urologe"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0497|cit497","first-page":"1591","article-title":"CCNU, bleomycin, and methylprednisolone with or without adriamycin in renal cel carcinoma: a randomized trial","volume":"61","author":"Richards","year":"1977","journal-title":"Cancer Treatment Reports"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/jco.2011.29.7_suppl.309","article-title":"AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study","volume":"29","author":"Rini","year":"2011","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"24","key":"10.1002\/14651858.CD013798.pub2-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1002\/cncr.27632","article-title":"AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study","volume":"118","author":"Rini","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bju.15165","article-title":"Randomised phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)","volume":"126","author":"Rodriguez-Vida","year":"2020","journal-title":"BJU international"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0501|cit501","unstructured":"HEBERFERON in renal cell carcinoma who.int\/trialsearch\/Trial2.aspx?TrialID=RPCEC00000229 2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0502|cit502","first-page":"S644","article-title":"Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC) - final Italian results","volume":"49","author":"Sternberg","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"468.e1","DOI":"10.1016\/j.clgc.2021.03.018","article-title":"Q-TWiST analysis of tivozanib versus sorafenib in patients with advanced renal cell carcinoma in the TIVO-3 study","volume":"19","author":"Szarek","year":"2021","journal-title":"Clinical Genitourinary Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"European Urology"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase Ib\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1002\/14651858.CD013798.pub2-BIB0506|cit506","first-page":"2702","article-title":"Erratum: phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0507|cit507","first-page":"viii74","article-title":"Determination of a new recist threshold using everolimus treatment in metastatic renal cell carcinoma: evaluation from the RECORD-1 study","volume":"8","author":"Thiam","year":"2010","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2004.06.155","article-title":"Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the german cooperative renal carcinoma chemoimmunotherapy group (DGCIN)","volume":"22","author":"Atzpodien","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0509|cit509","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/jco.2015.33.15_suppl.4523","article-title":"SWOG 1107: parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (pts) with papillary renal cell carcinoma (pRCC)","volume":"33","author":"Twardowski","year":"2015","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0510|cit510","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/KCA-170018","article-title":"Parallel (randomized) phase II evaluation of tivantinib (ARQ197) and tivantinib in combination with erlotinib in papillary renal cell carcinoma: SWOG S1107","volume":"1","author":"Twardowski","year":"2017","journal-title":"Kidney Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5301\/tj.5000699","article-title":"TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery","volume":"104","author":"Verzoni","year":"2018","journal-title":"Tumori"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013798.pub2-BIB0512|cit512","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/jco.2015.33.15_suppl.4522","article-title":"A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features","volume":"33","author":"Voss","year":"2015","journal-title":"Journal of Clinical Oncology: ASCO annual meeting proceedings"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0513|cit513","doi-asserted-by":"crossref","first-page":"v516","DOI":"10.1093\/annonc\/mdz253.094","article-title":"Results from a randomised phase I\/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)\/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)","volume":"30","author":"Voss","year":"2019","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF00873807","article-title":"A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma","volume":"13","author":"Witte","year":"1995","journal-title":"Investigational New Drugs"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0515|cit515","first-page":"449","article-title":"ADAPT: an ongoing international phase 3 randomized trial of autologous dendritic cell immunotherapy (AGS 003) plus standard treatment in advanced renal cell carcinoma (RCC)","volume":"32","author":"Wood","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0516|cit516","first-page":"257","article-title":"Final data analysis supports tivozanib as superior treatment for patients with RCC","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0517|cit517","unstructured":"Yang JC Haworth L Steinberg SM Rosenberg SA Novotny W A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer Proceedings of The American Society of Clinical Oncology 2002 21 Pt 1 5a, Abstract 15"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0518|cit518","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0519|cit519","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1200\/JCO.2016.34.15_suppl.4565","article-title":"Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): preliminary results from a randomized phase II clinical trial","volume":"34","author":"Zhou","year":"2016","journal-title":"Journal of Clinical Oncology. Conference"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0520|cit520","doi-asserted-by":"crossref","first-page":"e702","DOI":"10.1634\/theoncologist.2018-0839","article-title":"Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial","volume":"24","author":"Zhou","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0521|cit521","first-page":"195","article-title":"Efficacy of sunitinib in the treatment of advanced renal cellcarcinoma and its effect on survival time [Chinese]","volume":"7","author":"Liu","year":"2017","journal-title":"Anti-Tumor Pharmacy"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0522|cit522","unstructured":"Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01217931"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0523|cit523","unstructured":"Tivantinib with or without erlotinib hydrochloride in treating patients eith metastatic or locally advanced kidney cancer that cannot be removed by surgery https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01688973"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0524|cit524","unstructured":"A Study of famitinib in patients with advanced metastatic renal cell cancer https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01829841"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0525|cit525","unstructured":"Cabozantinib or sunitinib malate in treating participants with metastatic variant histology renal cell carcinoma https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03541902"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0526|cit526","unstructured":"A randomized, open-label, 2-arm, multicentre, phase II study to evaluate the safety and efficacy of trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination with sunitinib compared with sunitinib alone as first line treatment for patients with metastatic renal-cell carcinoma (mRCC). - Decavarec study TRX 1.0 who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-002556-41-AT 2008"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0527|cit527","unstructured":"TWIST. Randomized prospective phase II study of temsirolimus with or without low-dose interferon alpha in metastatic non-clear renal cell carcinoma: GOIRC study 02\/2008 - TWIST trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2008-000928-71-IT 2008"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0528|cit528","unstructured":"TWIST. Randomized prospective phase II study of temsirolimus with or without low-dose interferon alpha in metastatic non-clear renal cell carcinoma: GOIRC study 02\/2008 - TWIST who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-000928-71-IT 2008"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0529|cit529","unstructured":"Nivolumab with or without bevacizumab or ipilimumab before surgery in treating patients with metastatic kidney cancer that can be removed by surgery clinicaltrials.gov\/ct2\/show\/NCT02210117 2014"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0530|cit530","unstructured":"A study to test combination treatments in people with advanced renal cell carcinoma (FRACTION-RCC) clinicaltrials.gov\/ct2\/show\/NCT02996110 2016"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0531|cit531","first-page":"226","article-title":"A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (suniforecast)","volume":"43 Suppl 1","author":"Ahrens","year":"2020","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0532|cit532","doi-asserted-by":"crossref","unstructured":"Ahrens M Escudier B Haanen JB Boleti E Goupil MG Grimm MO A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) Journal of Clinical Oncology. Meeting Abstract | 2021 ASCO Annual Meeting I 2021","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4597"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0533|cit533","first-page":"74","article-title":"An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)","volume":"44 Suppl 2","author":"Ahrens","year":"2021","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0534|cit534","first-page":"73","article-title":"A randomised phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)","volume":"41","author":"Ahrens","year":"2018","journal-title":"Oncology Research and Treatment"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0535|cit535","first-page":"236","article-title":"A phase 2, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma - SUNNIFORECAST","volume":"51","author":"Rexer","year":"2020","journal-title":"Aktuelle Urologie"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0536|cit536","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00120-017-0397-1","article-title":"Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41\/16 of the AUO: a phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma.","volume":"56","author":"Rexer","year":"2017","journal-title":"Urologe"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0537|cit537","unstructured":"Pembrolizumab (MK-3475) plus epacadostat vs standard of care in mRCC (KEYNOTE-679\/ECHO-302) clinicaltrials.gov\/ct2\/show\/NCT03260894 2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0538|cit538","doi-asserted-by":"crossref","unstructured":"Aggarwal RR Thomas S Hauke RJ Nordquist LT Munster PN RENAVIV: a randomized phase III, double-blind, placebo-controlled study of pazopanib with or without abexinostat in patients with locally advanced or metastatic renal cell carcinoma Journal of Clinical Oncology (Conference) 2019","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS681"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0539|cit539","unstructured":"A study of bempegaldesleukin (NKTR-214: BEMPEG) in combination with nivolumab compared with the investigator's choice of a tyrosine kinase inhibitor (TKI) therapy (either sunitinib or cabozantinib monotherapy) for advanced metastatic renal cell carcinoma (RCC) clinicaltrials.gov\/ct2\/show\/NCT03729245 2018"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0540|cit540","doi-asserted-by":"crossref","unstructured":"Tannir NM Agarwal N Pal SK Cho DC Formiga M Guo J PIVOT-09: a phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC) Journal of Clinical Oncology. Meeting Abstract | 2020 Genitourinary Cancers Symposium 2020","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS763"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0541|cit541","first-page":"S39","article-title":"PDIGREE: an adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)","volume":"4","author":"Zhang","year":"2020","journal-title":"Kidney Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0542|cit542","doi-asserted-by":"crossref","unstructured":"Zhang T Ballman KV Choudhury AD Chen RC Watt C Wen Y PDIGREE: an adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704) Journal of Clinical Oncology. Meeting Abstract | 2021 Genitourinary Cancers Symposium 2019","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4596"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0543|cit543","doi-asserted-by":"crossref","unstructured":"Zhang T Ballman KV Choudhury AD Chen RC Watt C Wen Y PDIGREE: an adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704) Journal of Clinical Oncology (Conference) 2021","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS366"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0544|cit544","unstructured":"An immunotherapy study of nivolumab plus ipilimumab versus nivolumab alone in participants with advanced kidney cancer clinicaltrials.gov\/show\/NCT03873402 2019"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0545|cit545","unstructured":"A study of nivolumab combined with ipilimumab versus nivolumab alone in participants with advanced kidney cancer clinicaltrials.gov\/ct2\/show\/NCT03873402 2019"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0546|cit546","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/S2666-1683(20)36235-2","article-title":"A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk","volume":"21Suppl 3","author":"Choueiri","year":"2020","journal-title":"European Urology Open Science"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0547|cit547","first-page":"A209","article-title":"A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk","volume":"8","author":"Choueiri","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0548|cit548","first-page":"S2","article-title":"A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) of intermediate or poor risk","volume":"4 Suppl 1","author":"Choueiri","year":"2020","journal-title":"Kidney Cancer"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0549|cit549","first-page":"152","article-title":"A phase 3 study (Cosmic-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk","volume":"106","author":"De Giorgi","year":"2020","journal-title":"Tumori"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0550|cit550","unstructured":"SBRT with combination ipilimumab\/nivolumab for metastatic kidney cancer (CYTOSHRINK) clinicaltrials.gov\/ct2\/show\/NCT04090710 2019"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0551|cit551","unstructured":"Dendritic cell immunotherapy plus standard treatment of advanced renal cell carcinoma clinicaltrials.gov\/ct2\/show\/NCT04203901 2019"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0552|cit552","unstructured":"Study to evaluate the efficacy and safety of toripalimab in combination with axitinib versus sunitinib monotherapy in advanced renal cell cancer clinicaltrials.gov\/ct2\/show\/NCT04394975 2020"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0553|cit553","unstructured":"A study of TQB2450 injection combined with anlotinib hydrochloride capsule versus sunitinib in subjects with advanced renal cancer clinicaltrials.gov\/ct2\/show\/NCT04523272 2020"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0554|cit554","unstructured":"A study to compare bempegaldesleukin (BEMPEG: NKTR-214) combined with nivolumab and tyrosine kinase inhibitor (TKI) to nivolumab and TKI alone in participants with previously untreated kidney cancer that is advanced or has spread (PIVOT IO 011) clinicaltrials.gov\/ct2\/show\/NCT04540705 2020"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013798.pub2-BIB0555|cit555","first-page":"A447","article-title":"Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab\/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma","volume":"9","author":"Choueiri","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0556|cit556","unstructured":"An open-label, randomized phase 3 study of immune and targeted combination therapies, as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-002216-52-CZ 2021"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0557|cit557","unstructured":"A study of pembrolizumab (MK-3475) in combination with belzutifan (MK-6482) and lenvatinib (MK-7902), or pembrolizumab\/quavonlimab (MK-1308A) in combination with lenvatinib, versus pembrolizumab and lenvatinib, for treatment of advanced clear cell renal cell carcinoma (MK-6482-012) clinicaltrials.gov\/ct2\/show\/NCT04736706 2021"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0558|cit558","doi-asserted-by":"crossref","first-page":"S722","DOI":"10.1016\/j.annonc.2021.08.113","article-title":"717TiP randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)","volume":"32 Suppl 5","author":"Rini","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0559|cit559","unstructured":"A clinical trial to compare the effectiveness of savolitinib plus durvalumab relative to sunitinib for the treatment of renal cell cancer trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-000336-55-ES 2021"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0560|cit560","unstructured":"Savolitinib plus Durvalumab versus sunitinib and Durvalumab monotherapy in MET-Driven, unresectable and locally advanced or metastatic PRCC clinicaltrials.gov\/ct2\/show\/NCT05043090 2021"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0561|cit561","unstructured":"Axitinib +\/- Pembrolizumab in first line treatment of mPRCC clinicaltrials.gov\/ct2\/show\/NCT05096390 2021"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.conctc.2019.100403","article-title":"Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): a study protocol for phase III randomized sequential open-label study","volume":"15","author":"Kadono","year":"2019","journal-title":"Contemporary Clinical Trials Communications"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0563|cit563","unstructured":"Efficacy and safety of cytokines versus sunitinib as first-line followed by second-line axitinib in the treatment of patients with metastatic renal cell carcinoma: a phase III randomized sequential open-label study upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000014557 2013"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0564|cit564","first-page":"1","article-title":"Treatment of metastatic renal cell carcinoma: latest evidence and ongoing challenges","volume":"11","author":"Aguiar","year":"2018","journal-title":"Clinical Medicine Insights: Urology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0565|cit565","unstructured":"Aldin A First-line therapy for adults with advanced renal cell carcinoma - supplementary file Open Science Framework 2023 10.17605\/OSF.IO\/HXBG5"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0566|cit566","unstructured":"Cancer Facts & Figures 2022 Atlanta: American Cancer Society 2022"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0567|cit567","unstructured":"American Society of Clinical Oncology Kidney cancer: introduction https:\/\/www.cancer.net\/cancer-types\/kidney-cancer\/introduction#:~:text=Renal%20cell%20carcinoma%20is%20the,filtration%20units%20in%20each%20kidney."},{"key":"10.1002\/14651858.CD013798.pub2-BIB0568|cit568","unstructured":"American Society of Clinical Oncology Kidney Cancer: Statistics https:\/\/www.cancer.net\/cancer-types\/kidney-cancer\/statistics"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0569|cit569","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","article-title":"Efficacy and safety of first-line systemic therapy for metastatic renal cell aarcinoma: a systematic review and network meta-analysis","volume":"37","author":"Bosma","year":"2022","journal-title":"European Urology Open Science"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0570|cit570","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0571|cit571","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0572|cit572","doi-asserted-by":"crossref","first-page":"175628722110531","DOI":"10.1177\/17562872211053189","article-title":"Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis","volume":"13","author":"Cattrini","year":"2021","journal-title":"Therapeutic Advances in Urology"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"10","key":"10.1002\/14651858.CD013798.pub2-BIB0574|cit574","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0575|cit575","doi-asserted-by":"crossref","unstructured":"Chaimani A Caldwell DM Li T Higgins JP Salanti G Chapter 11: Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 training.cochrane.org\/handbook 2019","DOI":"10.1002\/9781119536604.ch11"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0576|cit576","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0577|cit577","unstructured":"CINeMA Nikolakopoulou A Higgins JP Papakonstantinou T Chaimani A Del Giovane C Egger M The University of Bern, The Campbell Collaboration, The Cochrane Collaboration 2020"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0578|cit578","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001425","article-title":"Immunotherapy for advanced renal cell cancer","author":"Coppin","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013798.pub2-BIB0579|cit579","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00345-016-1773-y","article-title":"Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study","volume":"34","author":"Dabestani","year":"2016","journal-title":"World Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0580|cit580","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11136-017-1704-4","article-title":"Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma","volume":"27","author":"Groot","year":"2018","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0581|cit581","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane 2022 Available from www.training.cochrane.org\/handbook 2022"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0582|cit582","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/his.13735","article-title":"Grading of renal cell carcinoma","volume":"74","author":"Delahunt","year":"2019","journal-title":"Histopathology"},{"issue":"7-8","key":"10.1002\/14651858.CD013798.pub2-BIB0583|cit583","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0584|cit584","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22060","article-title":"Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation","volume":"22","author":"Edwards","year":"2018","journal-title":"Health Technology Assessment"},{"issue":"7109","key":"10.1002\/14651858.CD013798.pub2-BIB0585|cit585","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0586|cit586","doi-asserted-by":"crossref","first-page":"e1001603","DOI":"10.1371\/journal.pmed.1001603","article-title":"Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap","volume":"11","author":"Elliott","year":"2014","journal-title":"PLOS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0587|cit587","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0588|cit588","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0589|cit589","doi-asserted-by":"crossref","first-page":"i3507","DOI":"10.1136\/bmj.i3507","article-title":"When and how to update systematic reviews: consensus and checklist","volume":"354","author":"Garner","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0590|cit590","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0591|cit591","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2017.05.005","article-title":"GRADE guidelines 17: Assessing the risk of bias associated with missing participant outcome data in a body of evidence","volume":"87","author":"Guyatt","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0592|cit592","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/2326-6066.CIR-14-0193","article-title":"PD-1 blockade in renal cell carcinoma: to equilibrium and beyond","volume":"2","author":"Harshman","year":"2014","journal-title":"Cancer Immunology Research"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0593|cit593","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 training.cochrane.org\/handbook 2019","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0594|cit594","doi-asserted-by":"crossref","unstructured":"Higgins JP Eldridge S Li T Chapter 23: including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 training.cochrane.org\/handbook 2019","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0595|cit595","doi-asserted-by":"crossref","unstructured":"Higgins JP Deeks JJ Chapter 6: choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 training.cochrane.org\/handbook 2019","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0596|cit596","doi-asserted-by":"crossref","unstructured":"Higgins JP Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 16: special topics in statistics. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 training.cochrane.org\/handbook 2019","DOI":"10.1002\/9781119536604"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0597|cit597","first-page":"309","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","author":"Keir","year":"2007","journal-title":"Annual Review of Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0598|cit598","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0599|cit599","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 training.cochrane.org\/handbook 2019"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0600|cit600","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft Diagnostics, therapy and aftercare of renal cell carcinoma - Longversion 3.0 https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Nierenzellkarzinom\/Version_3\/LL_Nierenzellkarzinom_Langversion_3.0.pdf"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0601|cit601","doi-asserted-by":"crossref","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 training.cochrane.org\/handbook 2019","DOI":"10.1002\/9781119536604"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0602|cit602","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.21037\/apm-20-1884","article-title":"Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Annals of Palliative Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0603|cit603","doi-asserted-by":"crossref","first-page":"399\u2013410","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0604|cit604","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1442-2042.2009.02302.x","article-title":"2009 update on the classification of renal epithelial tumors in adults","volume":"16","author":"Lopez-Beltran","year":"2009","journal-title":"International Journal of Urology"},{"issue":"10","key":"10.1002\/14651858.CD013798.pub2-BIB0605|cit605","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0606|cit606","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00262-020-02684-8","article-title":"Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis","volume":"70","author":"Mori","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0607|cit607","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022 - NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"10","key":"10.1002\/14651858.CD013798.pub2-BIB0608|cit608","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ccell.2022.08.022","article-title":"Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors","volume":"40","author":"Nassar","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0609|cit609","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/JU.0000000000002252","article-title":"Clinical outcomes and adverse events after first-line.treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"207(1)","author":"Nocera","year":"2022","journal-title":"Journal of Urology"},{"issue":"24","key":"10.1002\/14651858.CD013798.pub2-BIB0610|cit610","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0611|cit611","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","article-title":"ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma","volume":"32","author":"Powles","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0612|cit612","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0613|cit613","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7555\/JBR.32.20170080","article-title":"Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis","volume":"32","author":"Qin","year":"2018","journal-title":"Journal of Biomedical Research"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0614|cit614","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","article-title":"First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"4","author":"Quhal","year":"2021","journal-title":"European Urology Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0615|cit615","unstructured":"R: A language and environment for statistical computing R Core Team 2019 R Foundation for Statistical Computing 2019"},{"issue":"6","key":"10.1002\/14651858.CD013798.pub2-BIB0616|cit616","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","article-title":"A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma","volume":"80","author":"Riaz","year":"2021","journal-title":"European Urology"},{"issue":"9669","key":"10.1002\/14651858.CD013798.pub2-BIB0617|cit617","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0618|cit618","unstructured":"Robert Koch Institute Cancer in Germany in 2017\/2018 https:\/\/www.krebsdaten.de\/Krebs\/EN\/Content\/Publications\/Cancer_in_Germany\/cancer_chapters_2017_2018\/cancer_germany_2017_2018.pdf?__blob=publicationFile 2021"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0619|cit619","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"25","key":"10.1002\/14651858.CD013798.pub2-BIB0620|cit620","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0621|cit621","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0622|cit622","unstructured":"R\u00fccker G Krahn U K\u00f6nig J Efthimiou O Schwarzer G netmeta: Network meta-analysis using frequentist methods. R package version 1.10 CRAN.R-project.org\/package=netmeta 2019"},{"issue":"9","key":"10.1002\/14651858.CD013798.pub2-BIB0623|cit623","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0624|cit624","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"7","key":"10.1002\/14651858.CD013798.pub2-BIB0625|cit625","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0626|cit626","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2017.08.010","article-title":"Systemic treatment of renal cell cancer: a comprehensive review","volume":"60","author":"Sanchez-Gastaldo","year":"2017","journal-title":"Cancer Treatment Reviews"},{"issue":"36","key":"10.1002\/14651858.CD013798.pub2-BIB0627|cit627","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2018.79.1905","article-title":"Epidemiology and risk factors for kidney cancer","volume":"36","author":"Scelo","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013798.pub2-BIB0628|cit628","first-page":"40","article-title":"meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0629|cit629","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-Analysis With R","author":"Schwarzer","year":"2015"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0630|cit630","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 training.cochrane.org\/handbook 2019","DOI":"10.1002\/9781119536604.ch15"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0631|cit631","first-page":"7","article-title":"Cancer statistics 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0632|cit632","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2018.12.006","article-title":"Methodological review showed correct absolute effect size estimates for time-to-event outcomes in less than one-third of cancer-related systematic reviews","volume":"108","author":"Skoetz","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0633|cit633","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0634|cit634","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013798.pub2-BIB0635|cit635","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.eururo.2010.10.029","article-title":"Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis","volume":"59","author":"Sun","year":"2011","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD013798.pub2-BIB0636|cit636","doi-asserted-by":"crossref","first-page":"335","DOI":"10.18553\/jmcp.2018.24.4.335","article-title":"The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma","volume":"24","author":"Swallow","year":"2018","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"11","key":"10.1002\/14651858.CD013798.pub2-BIB0637|cit637","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/pon.3758","article-title":"Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening","volume":"24","author":"Thekdi","year":"2015","journal-title":"Psycho-Oncology"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0638|cit638","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0639|cit639","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1467-985X.00207","article-title":"The value of the aggregate data approach in meta-analysis with time-to-event outcomes","volume":"164","author":"Tudur","year":"2001","journal-title":"Journal of the Royal Statistical Society: Series A (Statistics in Society)"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0640|cit640","volume-title":"TNM Classification of Malignant Tumours","author":"Union for International Cancer Control (UICC)","year":"2017"},{"key":"10.1002\/14651858.CD013798.pub2-BIB0641|cit641","unstructured":"United States Congress 2007 Food and Drug Administration Amendments Act (FDAAA) of 2007: public law no 110-85 govinfo.gov\/content\/pkg\/PLAW-110publ85\/pdf\/PLAW-110publ85.pdf"},{"issue":"5","key":"10.1002\/14651858.CD013798.pub2-BIB0642|cit642","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011673","article-title":"Immunotherapy for metastatic renal cell carcinoma","author":"Unverzagt","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"18","key":"10.1002\/14651858.CD013798.pub2-BIB0643|cit643","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/molecules24183214","article-title":"Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0644|cit644","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00345-018-2447-8","article-title":"WHO\/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies","volume":"36","author":"Warren","year":"2018","journal-title":"World Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD013798.pub2-BIB0645|cit645","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"20","key":"10.1002\/14651858.CD013798.pub2-BIB0646|cit646","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki - ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"Journal of the American Medical Association"},{"issue":"12","key":"10.1002\/14651858.CD013798.pub2-BIB0647|cit647","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013798","article-title":"First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis","author":"Goldkuhle","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:24:27Z","timestamp":1759991067000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013798.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":656,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013798.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]}}}